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ABSTRACT 
Colorectal tumors are responsible for more than 600  000 deaths per year worldwide and 
thereby constitute the second most common cause of cancer related mortality. Early detection 
is related to improved prognosis and identification of genetic biomarkers would meliorate 
available diagnostic tools. Existing tumor classification systems lack precise monitoring 
within individual tumor stages in relation to progression. Therefore, we performed genetic 
characterization of tumor progression by analyses of colorectal tumors and normal colon 
mucosa.  We used combined microarray analysis to obtain a set of candidate biomarkers, 
starting with genome-wide array-based DNA analyses to screen for tumor-specific aberrant 
DNA patterns followed by correlations to the associated changes in mRNA and microRNA 
expression. We also investigated the relation between functional p53 and tumor progression 
as well as survival in patients with colorectal cancer (CRC). Furthermore, we used high 
resolution oligonucleotide array based CGH to identify nonpolymorphic structural variation in 
DNA from normal colon biopsies from patients with confirmed CRC to reveal candidate 
regions with association to putative familial CRC genetic variants.   
Colorectal tumor progression is proposed to follow a step-wise transformation from normal 
cells into malignant tumors, and therefore we used different stages within this model to 
summarize our results, in terms of genetic events of potential importance. First, gain in parts 
of chromosome 20 encompassing AURKA, as well as alterations in p53 (17p13.1), may be 
involved in the development from adenoma to carcinoma. Second, loss of 18q and gain of 8q 
harboring SMAD7 and PTP4A3 appear to rise during progression defined as early (Dukes A 
and B) to late (Dukes C and D) tumor stage. Third, distant metastatic potential may be 
associated to loss of 8p and increased expression of miR-373. Fourth, putative structural 
variants observed in normal colon mucosa may predispose for the onset of malignant 
transformation in familial sporadic CRC. Finally, there is a clear relationship between 
increased properties of aberrant DNA content as well as the number of combined genetic 
events and tumor progression.  
We conclude that correlated changes in DNA and RNA abundance may represent a robust 
rationale for selection of genetic biomarkers. Moreover, our results also suggest that Dukes D 
tumors possibly develop in a way that does not fit into the stepwise progression model, 
illustrated by earlier onset and less genetic aberrations.  These results represent a set of 
genetic events that can hopefully contribute to improved procedures considering diagnosis 
and prognosis in CRC patients by providing genetic biomarkers.   
 POPULÄRVETENSKAPLIG SAMMANFATTNING 
 
POPULÄRVETENSKAPLIG SAMMANFATTNING 
 
Varje år avlider mer än 600 000 människor i världen av cancer i tjock- och ändtarm, som är 
den tredje vanligaste cancerformen och näst vanligaste cancerrelaterade dödsorsaken i Sverige 
och världen. De patienter som diagnostiseras med tjock- eller ändtarmscancer på ett tidigt 
stadium har större möjligheter till en tidigare insatt behandling och därmed oftast en bättre 
prognos. Därför är det viktigt att kunna identifiera tidiga tecken på cancersjukdom samt att 
förstå den genetiska orsaken till varför vissa tumörer sprider sig (metastaserar).  
 
Cancer är en genetisk sjukdom, som uppkommer genom förändringar i cellernas arvsmassa. 
Arvsmassan består av kromosomer som innehåller DNA. I DNA-sekvensen finns gener som 
fungerar som ritmall för de proteiner som cellerna behöver tillverka för sin funktion. Som 
budbärare mellan DNA och proteiner använder kroppen ytterligare en molekyl som kallas 
RNA. I denna avhandling har både kromosomer, DNA och RNA studerats i tumörceller från 
tjock- och ändtarmscancer och jämförts med arvsmassa från normala celler. Kromosomala 
avvikelser innebär att den normala sammansättningen av DNA är rubbad, vilket kan ge 
upphov till förändringar i de proteiner som generna kodar för.  Fundamentalt för avhandlingen 
var att förstå tumörernas genetiska ursprung och utveckling (progression). 
 
Vi har använt avancerade DNA-tekniker som möjliggör analys av hela det mänskliga genomet 
på samma gång. Tusentals fragment av arvsmassa (DNA), gener (DNA eller RNA) och 
kontrollelement för hur generna styrs (mikroRNA), mäts genom att man kopplar olika färger 
till DNA, RNA och mikroRNA och jämför skillnaderna i färgintensitet mellan tumörceller 
och normalceller. Denna teknik kallas microarray och har utvecklats under det senaste 
årtiondet.  
 
De tumörspecifika kromosom förändringar som identifierades, kopplades sedan till olika 
stadier av sjukdomen, från den enklaste formen då patienten har god prognos till avancerad 
metastaserande cancer med dålig prognos. Vi studerade även överlevnad, genom att jämföra 
patienter som friskförklarats och överlevt mer än tio år efter operation med patienter som 
avlidit inom ett år efter operation, till följd av tumörsjukdom. Resultatet visade att mycket 
tydliga förändringar i stora delar av kromosom åtta var kopplade till metastaserande tumörer 
och tumörer från patienter med kort överlevnad. Stora avvikelser identifierades också i andra 
kromosomer med koppling till andra tumörstadier.  
 
I nästa steg jämförde vi därför om det fanns en koppling mellan generna och deras 
proteinprodukter. För att få en uppfattning om hur mycket proteinproduktionen ökar eller 
minskar som en följd av genförändringen, mäter man RNA. Våra resultat visade att 
kromosom 20 i samtliga tumörstadier innehöll gener som var förändrade på både DNA- och 
RNA- nivå och därigenom troligen är kopplade till tumöruppkomst. En av generna, AURKA, 
har tidigare kopplats till ett förstadium till tumörer i tjock- och ändtarm. p53 är en annan gen 
som är viktig för tumörutveckling, men som enligt vår studie saknade betydelse för prognos. 
Totalt identifierades 36 gener och två mikroRNA som kopplades till metastaserande tumörer POPULÄRVETENSKAPLIG SAMMANFATTNING 
 
och som återfanns på kromosom 7, 8, 13 och 18.  Dessa gener bör vidare studeras genom 
utökade analyser, för att konfirmera om de kan kandidera som prognosmarkörer.  
 
Dagens forskare ägnar stort fokus åt att identifiera skillnader i den normala mänskliga 
arvsmassans sammansättning. På så vis hoppas man kunna koppla dessa skillnader, som är 
betydligt fler än förväntat, till olika sjukdomstillstånd, tex. cancer. I det fjärde delarbetet 
undersökte vi DNA från normal tarmslemhinna och blod från patienter med cancer i tjock- 
och ändtarm och fann ett antal DNA förändringar som potentiellt kan komma att kopplas till 
en ökad risk att utveckla sjukdom (familjära riskfaktorer). Dessa förändringar behöver dock 
verifieras i DNA från ett större antal patienter. 
 
Sammantaget har våra analyser resulterat i en mängd fynd i arvsmassa med kopplade 
genetiska förändringar som förhoppningsvis kan leda till en förbättrad diagnostik och/eller 
prognosbedömning av patienter med tumörer i tjock- och ändtarm. ORIGINAL PAPERS 
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INTRODUCTION 
Tumor Development and Progression 
For more than half a century, huge efforts including considerable financial investments have 
been assigned investigations of tumor genetics, to understand and ultimately defeat malignant 
disease. These efforts provide substantial amounts of genetic data within the field of cancer, 
that most likely harbor numerous therapeutic targets that will hopefully be uncovered within a 
reasonable period of time.  
Paradigms of Genetics 
Tumor biology describes development and transformation of normal cells to malignant 
neoplastic cells – in other words, tumorigenesis. Scenarios involved in cancer formation can 
be described by parallels to historical paradigms from genetic research, from G Mendel and C 
Darwin to currently active scientists like e.g. B Vogelstein, R Weinberg and 2006 Nobel Prize 
winner in Medicine and Physiology, A Fire. The choice of these scientists among many 
successful coworkers worldwide was based on the fact that their research has provided 
essential evidence in the field of genetics and biology for the understanding of parts in tumor 
biology that are central for the specific contents in this thesis.   
 
In synopsis, the scientific observations by Mendel and Darwin conclude the very basics of 
genetics and modern evolutionary biology, namely natural selection together with clonal 
growth advantages.  Observations from human cancers and animal models argue that the 
progressive conversion of normal human cells into tumor cells follows a process analogous to 
evolutionary biology. Hence, the obtained genetic changes give rise to growth advantages 
subsequently leading to tumor development (Foulds 1954; Nowell 1976; Hanahan and 
Weinberg 2000).   
Genetic Instability 
Human cancer is a genetic disease and thus, understanding the molecular basis of tumor 
associated genetic defects is crucial. Genetic instability illustrates these defects and represents 
the focus in each of the papers described and discussed in this thesis. Genetic instability refers 
to alterations in genomic structure and is typically categorized into two major classes, 
comprising instability at chromosome  or nucleotide level (Nowak, Komarova et al. 2002).  
 
Tumors with chromosomal instability, CIN, represent the majority and display either 
numerical aberrations i.e. aneuploid karyotype, which refer to abnormal numbers of 
chromosomes in tumor cells (Boveri 1914) or structural aberrations. The later is further 
subdivided into balanced and unbalanced instabilities.  
 
Balanced instabilities most commonly refer to chromosomal translocations and were until 
recently mainly associated to hematological malignancies, but now also reported in solid 
tumors (Rabbitts 1994; Mitelman, Johansson et al. 2004).  Translocations are often related to 
a specific tumor type and either cause chimeric fusion genes or altered expression of INTRODUCTION 
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structurally normal genes, and can therefore also be used as diagnostic biomarkers (Frohling 
and Dohner 2008). No tumor specific chromosomal translocation in colorectal tumors has yet 
been identified. 
 
Unbalanced instabilities are typically gains and losses of various size located throughout the 
genome. Many of these rearrangements are considered to be secondary events for tumor 
formation and sometimes involved in tumor progression. In colorectal tumors, gain of 
chromosome 8q is related to a more aggressive behavior and a less favorable prognosis 
(Ghadimi, Grade et al. 2003). The functional consequences of the majority of unbalanced 
instabilities are still unknown although a number of genes within altered regions, such as p53, 
MYC and ERBB2, have been identified and characterized in relation to cancer. Amplification 
of ERBB2 and subsequent overexpression of the protein represents a target for the monoclonal 
antibody Trastuzumab, which is mainly used in treatment of breast cancer patients (Romond, 
Perez et al. 2005). Amplification of ERBB2 also occurs in approximately 3 % of colorectal 
tumors (Nathanson, Culliford et al. 2003). 
 
Several chromosomal regions of recurrent gain and loss, but without any obvious target 
genes, have been associated to one or several cancer types. Discovery of new tumor related 
genes within these regions is facilitated by comparisons to corresponding expression profiles, 
in order to filter out specimens without differential expression. These regions may also 
contain noncoding genes, such as microRNAs, possibly affected by genomic alterations and 
consequently future putative anti-cancer targets. These aspects are further described in Paper 
II and III. However, the cause of CIN still remains poorly understood but implications in 
different pathways and processes have been proposed, including telomere and centromere 
dysfunction and inactivation of proteins involved in mitotic spindle and DNA replication 
checkpoints (Grady 2004).  
 
The  nucleotide related instability involves small-scale point mutations, subdivided into 
substitution, deletion or insertion of one or a few nucleotides.  Instability at the nucleotide 
level can arise from defective DNA repair systems, such as inactivation of DNA mismatch 
repair (MMR) genes MSH2 and MLH1 (Thibodeau, Bren et al. 1993; Peltomaki and Vasen 
1997). Consequently, errors at the nucleotide level that occur during replication can not be 
effectively repaired, which lead to increased rates of nucleotide sequence mutations. Deficient 
repair is detected by analysis of microsatellite instability (MSI) that is used for diagnosis of 
patients with Hereditary Non Polyposis Colon Cancer (HNPCC) (Boland, Thibodeau et al. 
1998). MSI is also involved in as many as 15% of sporadic colorectal tumors (Grady 2004).  
These cancers, unlike the majority of solid tumors (Lengauer, Kinzler et al. 1997), often retain 
a diploid karyotype, i.e. a normal set of chromosomes.  
Genetic events in tumorigenesis 
In 2000 Hanahan and Weinberg postulated the “Hallmarks of Cancer”, as a panel of six main 
control systems that monitor homeostasis within the cell and normally act as defense 
mechanisms toward tumor development (1-6 as indicated below). According to the authors, INTRODUCTION 
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disruption of these systems subsequently enables tumorigenesis and each of which will be 
presented below.  
 
Normal cells require mitogenic i.e. growth signals to proceed into an active proliferative state 
in the cell cycle. Tumor cells have an acquired capability of 1) self sufficiency in growth 
signals, which bring the cell to a more or less constant proliferative state. Responsible for the 
growth signal autonomy are excessively active oncogenes, consequently accelerating 
proliferation in the neoplastic cell. Yet another tumor cell characteristic is 2) insensitivity to 
antigrowth signals which would normally suppress growth by induced cellular differentiation 
or force the cell into a quiescent state. Instead, the tumor cells monitor antiproliferative 
signals by modified receptors or pathways related to Rb or p53 proteins and remain 
proliferative. The p53 protein and its role in tumor development and colorectal cancer will 
later be described in more detail (Figure 1). In contrast to the direct accelerated proliferation 
due to excess oncogenic activation, tumor suppressor genes (TSGs) repress antigrowth signals 
mechanisms and thus indirectly promote growth.  
 
©2007 From The Biology of Cancer by Robert A. Weinberg. Reproduced by permission of Garland Science/Taylor and Francis LLC.  
 
Figure 1. A variety of cell-physiological stresses cause rapid increase in p53 levels. Accumulation of p53 
subsequently induces a number of cellular responses leading to downstream effects.  
 
Moreover, the acquired resistance toward programmed cell death, to 3)  evade apoptosis 
allows tumor cells to survive and continue their growth despite circumstances such as cellular 
stress and genomic damage. Key regulators of apoptosis are the caspase proteins, a family of 
cysteine proteases that have been termed executioner proteins. In addition and independent of 
the growth limiting systems, tumor cells become immortalized by developing 4) limitless 
replicative potential.  Normal cells have a finite number of replication cycles, which is INTRODUCTION 
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determined by telomeric lengths denoted by the Hayflick limit (Hayflick 1965; Harley 2008), 
directly associated to successive telomeric chromosomal shortening. Tumor cells, however, 
develop abilities to maintain telomeres and thereby become immortalized.  
 
Since a continuous supply of nutrients and oxygen is essential for tumor as well as normal cell 
growth, induced and 5) sustained angiogenesis is necessary for the tumor to progress to a 
larger size.   The ultimate step of tumor progression involves 6) tissue invasion and metastasis 
which constitute the major cause of cancer related deaths. Metastatic spread involves cell-cell 
adhesion molecules (CAMs), extracellular matrix components and proteases, which 
mechanisms are complex and still incompletely understood (Mehlen and Puisieux 2006).   
 
In summary, Hanahan and Weinberg suggested that six cellular processes must be disrupted 
to enable transformation of a normal cell into its neoplastic counterpart. However, a recent 
sequence evaluation of colon and breast cancer genomes indicate that the number of altered 
cellular processes required for tumorigenesis may be even higher (Sjoblom, Jones et al. 2006).    
Clearly, certain genetic instability events affect essential cell cycle activities and regulation 
with evident tumor promoting consequences (Hanahan and Weinberg 2000). 
Oncogenes and Tumor Suppressor Genes 
At the gene level, DNA alterations such as gains, losses, translocations and point mutations 
may give rise to oncogenes and affect tumor suppressor genes. The first oncogene was 
discovered in 1976, when SRC was identified to manage transformation of normal cells into 
tumor cells mediated by Rous sarcoma virus (Stehelin, Varmus et al. 1976). Oncogenes 
accelerate growth in tumor cells and are formed by amplification, translocation or point 
mutation of their normal analogues, called protooncogenes. In colorectal and other cancers, 
mutated  K-RAS and MYC constitute well defined oncogenes (Forrester, Almoguera et al. 
1987; He, Sparks et al. 1998) which are frequently amplified in many cancer types. A novel 
colorectal oncogene, CDK8 was recently reported and locates within a recurrently amplified 
region on chromosome 13 (Firestein, Bass et al. 2008).   
 
Mutations and deletions are genetic events closely associated to tumor suppressor genes 
(TSGs) and results in alterations that partly or completely deplete the normal growth 
inhibiting abilities of the unaltered TSG. A classic example of a TSG is the Retinoblastoma 
(RB) gene, described in A Knudson’s twin-study of the retinoblastoma disease where the 
author presented his “two-hit hypothesis” (Knudson 1971).  According to the hypothesis, two 
genetic “hits” i.e. mutations (point mutations and allelic loss) affecting both DNA strands 
(alleles) in the cell, are required to ablate the TSG activity and thus promote tumor 
progression. However, today it is clear that yet other mechanisms such as DNA methylation 
serve as efficient silencers of tumor suppressor gene activity (Jones and Baylin 2002).  
 
In haploinsufficient genes, only one genetic event affecting one allele is required to cause 
functional inactivation and thereby enable tumorigenesis. In this case, the specific TSG need 
two functional copies of the gene to express a normal protein (Fero, Randel et al. 1998; INTRODUCTION 
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Santarosa and Ashworth 2004). Beside the RB gene, well characterized TSGs includes the 
APC gene that is frequently mutated in cancers and plays a central role in several cellular 
processes e.g. the WNT-signalling cascade (Nagase and Nakamura 1993; Fodde, Kuipers et 
al. 2001) and p53 that represents an haploinsufficient TSG (Santarosa and Ashworth 2004). 
Aspects of p53 is further described in Paper I. TSGs have been assigned still other important 
roles in tumor progression, due to their involvement in the maintenance of genomic integrity 
(Lengauer, Kinzler et al. 1997).  
p53-“Guardian of the Genome” 
The p53 protein was discovered in 1979 and has gained a lot of attention since then, titled 
“Molecule of the Year” in 1993 and currently, a p53 PubMed search results in more than 
50 000 hits. The p53 protein is a transcription factor (Vousden and Prives 2005) and in its 
normal condition represents an important factor in tumor surveillance. Accordingly, p53 was 
denoted “guardian of the genome” in 1992 (Lane 1992). The protein is implicated in several 
pathways and processes, namely differentiation, senescence, antiangiogenesis, cell cycle 
arrest and programmed cell death, indicating its fundamental roles in maintenance of cellular 
homeostasis (Lane 1992; Vousden and Lu 2002; Levine, Hu et al. 2006). 
 
Normally, cellular stress such as genetic damage, radiation or imbalanced mitogenic signals 
induces increased p53 expression that promotes p53 mediated cell growth inhibition and 
ultimately cell death through apoptosis. In the absence of cellular stress, the p53 interact with 
its main regulator MDM2 (Kubbutat, Jones et al. 1997) and other proteins that keep p53 
expression levels low to avoid otherwise harmful effects on normal growth and development. 
However, there are a number of ways by which the p53 protein is inhibited to mediate its 
regular activities in response to stress factors (Figure 1). p53 is mutated in more than 50% of 
human cancers and since p53 is a tumor suppressor gene, protein function is repressed or lost 
by mutations, most frequently missense, or deletion of the entire or parts of the gene (Harris 
1993).  In 1989, Baker et al. reported p53 mutation in one copy of the allele combined with 
deletion of the other in human colon cancers, thus fulfilling the cardinal criteria of the “two-
hit”-hypothesis (Baker, Fearon et al. 1989). However, p53 is not an ordinary TSG since it 
proved to be haploinsufficient in studies performed on p53 heterozygous mice 
(Venkatachalam, Shi et al. 1998). Hence, only one genetic event can be enough to silence the 
protein and thus, p53 does not follow the characteristic principle of TSGs. Furthermore, a 
mutated p53 protein may inhibit normal activity by interfering with wild-type p53 proteins 
during the formation of homotetramers, the functional p53 unit. The tetramer is thereby 
deactivated in a dominant–negative fashion, despite only one single p53 mutant protein 
participated in oligomerization (McLure and Lee 1998).  p53 was the target of analyses 
performed in Paper I. 
 
Regulation of gene expression 
Measurement of protein abundance is crucial. However, due to their complex structure and 
chemical properties, proteins are difficult to study in large scale experiments. Therefore, their INTRODUCTION 
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originators, mRNAs, are frequent targets for analysis and subsequent implication in tumors 
among other diseases. Apart from immediate gene expression studies, two further categories 
can explain or mirror altered expression, namely epigenetic events and post-transcriptional 
regulation by noncoding RNAs.  
 
Epigenetics describe effects such as chromatin structure remodeling or DNA methylation on 
gene transcription (Jones and Baylin 2002). In cancer, gene silencing by hypermethylation of 
promoter regions occur frequently and has been described in most tumor types (Herman and 
Baylin 2003).  Promoter hypermethylation of mismatch repair (MMR) gene MLH1 occur 
frequently in MSI positive colorectal tumors (Herman, Umar et al. 1998). Post-transcriptional 
regulation  involves  siRNA and microRNA that specifically downregulate mRNA levels 
through RNA-RNA base-pairing. Until recently, siRNAs were only identified endogenously 
in prokaryotic organisms although synthesized siRNAs have been frequently used for 
eukaryotic gene silencing for several years (Fire, Xu et al. 1998) (Watanabe, Totoki et al. 
2008). MicroRNAs, however, represent endogenous molecules and will be described below. 
microRNA 
A Fire together with C Mello received the Nobel Prize in Medicine and Physiology (2006) for 
discoveries about genetic silencing by small noncoding RNAs, also referred to as RNA 
interference. Fire’s work also comprise microRNAs, a class of noncoding RNAs that have 
gained a lot of focus during recent years, since they represent a promising target molecule for 
both diagnostics and treatment in complex genetic diseases, e.g. cancer.  As mentioned above, 
microRNAs are involved in translational regulation by binding to complementary sites in 
target mRNA transcripts and thereby mediate translational repression or transcript 
degradation (Pillai, Bhattacharyya et al. 2007).  
 
Today 718 human microRNAs have been discovered (mirBase version 13, NCBI36, update 
2009-03-08)(Griffiths-Jones, Saini et al. 2008) and the total number of microRNAs in the 
genome is estimated to several thousands. Furthermore, a single microRNA can be associated 
to and regulate a variable number of genes. Specific genes can interact with several 
microRNAs, for instance p53 that have been associated to 16 different microRNAs 
(miRBASE Target Database, Welcome Trust Sanger Institute, microrna.sanger.ac.uk). It is 
likely that microRNAs play essential roles in tumor development since expression profiles 
demonstrate that many microRNAs are downregulated in tumors compared to normal tissue 
(Blenkiron and Miska 2007). MicroRNAs have been attributed oncogenic potential and may 
also act as tumor suppressors (Negrini and Calin 2008).  The role of microRNAs in colorectal 
tumorigenesis was investigated in Paper III. 
Tumor Progression 
In 1957, J Foulds defined tumor progression as the irreversible development of a neoplasm by 
stepwise qualitative changes of one or more of its characters (Foulds 1957). Later, Foulds and 
other authors suggested that this biological and clinical progression may reflect a sequential 
increase of genetically altered cellular subpopulations of tumors, gaining new characteristics INTRODUCTION 
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(Cairns 1975; Nowell 1976; Nowell 1986). Today, scientists such as R Weinberg have 
provided robust models of the synthesized current knowledge applied in a genetic context, 
comprising different genetic events within altered pathways. These models either reflect 
tumor progression in general or are typical for a specific tumor type, like colorectal cancer 
(e.g. the Vogelstein model, described below). In summary, normal cells evolve into cells with 
increasingly neoplastic phenotype during a sequence of randomly occurring structural DNA 
alterations and epigenetic events, driving tumor progression. This theory is denoted the clonal 
evolution theory (Nowell 1976). Malignant cell phenotypes thereby emerges through 
progression based on these genetic events and subsequently altered pathways, described 
above (the Hallmarks of Cancer), in favor of the cancer phenotype. Beside the clonal 
evolution theory, the cancer stem cell theory has gained a lot of interest the last decade, where 
tumor initiation occurs in a stem or progenitor cell (Boman and Huang 2008). 
Colorectal Cancer  
Cancer of the colon and rectum constitutes two separate cancer types but are referred to as 
colorectal cancer (CRC), since they share a lot of characteristic properties. CRC is the third 
most common among cancers and the second cause of cancer related death worldwide and in 
Sweden. Risk factors for development of colorectal tumors include tobacco smoking, a diet 
high in total fat and meat, obesity and sedentary lifestyle. Detection of hemoglobin (F-Hb) in 
feces was recommended for CRC screening by the European Commission in 2003, together 
with colonoscopy, which is used as the main screening tool for colorectal polyps and tumors 
in the United States and several European countries (WHO 2002; ACS 2007; Epidemiologiskt 
Centrum 2007; Cancerfonden 2008). Colonoscopy decrease CRC incidence through early 
detection and removal of polyps and thus decrease mortality (Winawer, Zauber et al. 1993). 
Surgery is the primary treatment strategy and some patient groups further receive preoperative 
radiotherapy (rectal cancers) and adjuvant treatment by chemotherapy.  
 
CRC can be subdivided into hereditary (< 5 %), familial (20-25 %) and sporadic (75 %) 
disease (www.cancer.gov) (Cardoso, Boer et al. 2007; NCI 2009). Thus, dominantly inherited 
variants only accounts for a small fraction of colorectal tumors, among which hereditary 
nonpolyposis colon cancer (HNPCC) and familiar adenomatous polyposis (FAP) are the most 
common and well defined. Hereditary CRCs are based on specific genetic alterations that give 
rise to colorectal tumors, typically with an earlier onset possibly caused by a faster 
development from adenoma to carcinoma (Cheah 2009). Nevertheless, patients with 
hereditary variants have improved survival compared to patients with sporadically occurring 
tumors (Lynch and de la Chapelle 2003).   
 
Among patients with sporadic disease, several carry a familiar risk genotype (Goldgar, Easton 
et al. 1994; Easton and Eeles 2008), not to be confused with well characterized hereditary 
disease. However, genetic loci responsible for the risk genotype are largely unknown but, 
interestingly, sibling studies have estimated that approximately 35% of all CRC cases can be 
attributed to genetic susceptibility (Lichtenstein, Holm et al. 2000). Furthermore, recent 
studies suggest even higher rates based on the presence of rare predisposing genetic variants INTRODUCTION 
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(McCarroll, Kuruvilla et al. 2008) (Described below, Future CRC Prediction and 
Diagnostics).  However, the work summarized in this thesis was primarily focused on 
bringing further clarity into the genetic events implicated in malignant progression of sporadic 
colorectal tumors. 
Tumor Staging 
Detailed pathological analyses have provided evidence for the multistep sequence of events 
that give rise to most cancer types. Colorectal tumors are of epithelial origin and 
pathologically classified into three major categories, namely nonneoplastic polyps, neoplastic 
polyps (premalignant adenomas) and cancers. The cancer category represents 95% of all 
colorectal tumors and constitutes the focus of this thesis.  For many years, Dukes 
classification system (Dukes and Bussey 1958) (Table 1) was the golden standard for tumor 
staging by pathologists worldwide. Today, the TNM-system has replaced Dukes for 
classification of the anatomic extent of cancer spread (Table 1) (Sobin and Fleming 1997). In 
this thesis, however, the Dukes A-D classification has been used for tumor staging in relation 
to progression. 
 
Table 1. TNM classification describes the local, regional and distant extent of solid tumor spread and is 
considered the standard cancer staging system. Dukes staging system is specific for colorectal tumor 
classification and was earlier considered the standard strategy for CRC staging. 
Dukes Tumor  spread/localization TNM*
    
A  Submucosa  
Muscularis propria 
T1, N0, M0 
T2, N0, M0 
     
B  Beyond muscularis propria 
Adjacent organs 
T3, N0, M0 
T4, N0, M0 
     
C  1-3 lymph node metastasis 
≥ 4  lymph nodes metastasis 
T1-4, N1, M0 
T1-4, N2, M0 
     
D  Distant organ metastasis  T1-4, N0-2, M1 
   
* T = local extent of primary tumor; N = regional lymph nodes; M = distant metastasis, N0 or M0 = no lymph 
nodes or distant metastases. 
Genetic Instability in colorectal tumors 
In sporadic CRC, CIN (85 % of all cases) and MSI (15 %) characterize genetic instability 
pathways and few examples of balanced instabilities, i.e. translocations, have been identified 
in colorectal tumors. Until recently, the reports on translocations in solid tumors were fairly 
limited and primarily associated to hematological malignancies (Rabbitts 1994; Mitelman, 
Johansson et al. 2004). This possibly reflects the more pronounced complexity in solid tumors 
which hence demands intricate characterization and selection among numerous genetic events 
of putative importance. However, MSI tumors predominantly display a diploid karyotype, 
while CIN type tumors are generally aneuploid (Lengauer, Kinzler et al. 1997). Nevertheless, 
MSI and CIN CRC tumors both display APC and K-RAS mutations that occur during 
transformation from normal epithelium to malignant carcinoma (Grady 2004). 
The Microsatellite Instability pathway (MSI) 
MSI tumors result from inactivation of crucial genes involved in the mutation mismatch 
repair (MMR) system and thereby promotes tumorigenesis through generation of target gene INTRODUCTION 
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mutations.  As mentioned above, MSI is characteristic for HNPCC but also found in as many 
as 15 % of sporadic tumors (Grady 2004). Genes involved and inactivated by either mutation 
or hypermethylation include MSH2, MSH3, MSH6, MLH1, PMS1 and PMS2 . 
The Chromosomal Instability pathway (CIN)   
CIN tumors carry considerable proportions of structural variation in terms of gained and lost 
chromosomal regions, recurrently identified on chromosomes 7, 8, 13, 18 and 20 (Ried, 
Heselmeyer-Haddad et al. 1999; Hermsen, Postma et al. 2002; Lagerstedt, Staaf et al. 2007; 
Camps, Grade et al. 2008). The origin of CIN is elusive, as previously mentioned, but 
involvement of the APC gene has been proposed (Fodde, Kuipers et al. 2001). Mutations in 
p53, loss of SMAD7 and amplification of AURKA are gene specific events presented in 
several reports for implication in CIN mediated tumor progression (Fearon and Vogelstein 
1990; Lagerstedt, Kressner et al. 2005; Broderick, Carvajal-Carmona et al. 2007; Carvalho, 
Postma et al. 2009). The roles and order of these genes and genetic events in relation to 
colorectal tumor progression are further described in the next section.    
Vogelgram – a progression model for colorectal cancer 
In 1990, B Vogelstein and coworkers presented the multistep model for colorectal 
carcinogenesis, the “Vogelgram” (Fearon and Vogelstein 1990) (Figure 2) and since then the 
model has been adopted and used by researchers worldwide. The Vogelgram is still 
considered valid, although a number of genetic events need to be added in order to obtain a 
refined picture. The adenoma to carcinoma sequence is initiated by inactivation of APC 
(5q21) which takes place in the normal epithelium, resulting in accumulation of beta-catenin 
that subsequently increase during stepwise development. The next genetic event involves 
hypomethylation and occurs in the state of a hyperplastic polyp. K-ras mutations are 
identified in slightly larger adenomas following loss of 18q-arm during transition to late 
adenomas. Several TSGs, such as SMAD7, involved in TGF-β and WNT-signaling (Broderick, 
Carvajal-Carmona et al. 2007), have been suggested as the target gene for 18q loss. 
Ultimately, loss of the 17p-arm includes the p53 gene in the final progression from late 
adenoma to carcinoma (Fearon and Vogelstein 1990).   
 
Figure 2. Transformation of normal colon epithelium into malignant carcinoma by step-wise accumulation of 
five genetic aberrations, as presented by Fearon and Vogelstein in 1990. This progression model for colorectal 
tumorigenesis is referred to as the “Vogelgram”.  * = the region is proposed to harbor a tumor suppressor gene 
(TSG). 
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Yet other genes and genetic events have been proposed to contribute to colorectal tumor 
development and metastasis since the presentation of the Vogelgram.  Gain of chromosome 
20q has been observed in adenomas and AURKA represents a candidate oncogene located at 
20q13.2 (Carvalho, Postma et al. 2009). Recently CDK8, that is located within the frequently 
amplified chromosome 13 (13q12.3), was suggested to display oncogenic abilities in colon 
cancer cell lines by regulation of β-catenin activity (Firestein, Bass et al. 2008). Moreover, 
recurrent loss of the 18q-arm indicates the presence of potential tumor suppressor genes. 
SMAD7 map to 18q21.1 and has gained a lot of attention lately since it contains a SNP-site 
proposed a CRC susceptibility locus (Broderick, Carvajal-Carmona et al. 2007). Late 
chromosomal abnormalities in colorectal tumorigenesis involve loss of the 8p-arm but no 
associated TSG has yet been identified. However, PTP4A3 (PRL-3) is located to the 8q24.3-
region that is often amplified in late stage colorectal tumors and has been related to metastasis 
(Saha, Bardelli et al. 2001). Some of these genes will be further discussed later in this thesis. 
Structural and Copy Number Variation  
Structural variation, also referred to as copy number variation (CNV), encompass single 
nucleotide-- to megabase-sized structural variants of genomic segments such as deletions, 
segmental duplications, insertions, inversions or complex chromosomal rearrangements. In 
recent years, it has become clear that CNVs are more common and involves a much greater 
proportion of the human genome than previously realized (Iafrate, Feuk et al. 2004; Sebat, 
Lakshmi et al. 2004; Hinds, Stuve et al. 2005; Sharp, Locke et al. 2005; Tuzun, Sharp et al. 
2005; McCarroll, Hadnott et al. 2006; Redon, Ishikawa et al. 2006; Scherer, Lee et al. 2007; 
Wong, deLeeuw et al. 2007). The development of high resolution techniques have generated 
the ability to detect and catalogue CNVs en masse and further associate them with biological 
function and complex human genetic diseases (Carter 2007). Array-based analysis of single-
nucleotide polymorphisms (SNPs) is widely used for identification of variation and   
subsequent downstream applications. Multiple genome-wide association studies (GWAS) 
aimed to associate specific disease genotype to phenotype (McCarroll and Altshuler 2007) 
have recently identified several susceptibility SNP loci proposed to predispose for CRC 
(Tomlinson, Webb et al. 2007; Zanke, Greenwood et al. 2007; Houlston, Webb et al. 2008; 
Jaeger, Webb et al. 2008; Tenesa, Farrington et al. 2008; Tomlinson, Webb et al. 2008). 
Patterns of structural variation in CRC patients were analyzed in Paper II and IV. 
Future CRC Prediction and Diagnostics 
During the last years, several genome-wide association studies (GWAS) have presented a 
number of potential and valid risk sites for each of the four most prevalent cancer types, 
namely breast, prostate, colorectal and lung cancer (Easton and Eeles 2008). In colorectal 
cancer, ten risk SNP loci were recently discovered at chromosomal bands; 8q23.3 
(Tomlinson, Webb et al. 2008), 8q24 (Tomlinson, Webb et al. 2007; Zanke, Greenwood et al. 
2007), 10p14 (Tomlinson, Webb et al. 2008), 11q23 (Houlston, Webb et al. 2008; Tenesa, 
Farrington et al. 2008), 14q22 (Houlston, Webb et al. 2008), 15q13 (Tomlinson, Webb et al. 
2008), 16q22, (Houlston, Webb et al. 2008), 18q21 (Broderick, Carvajal-Carmona et al. 
2007), 19q13 and 20p12 (Houlston, Webb et al. 2008).  In these studies, large cohorts of INTRODUCTION 
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colorectal cancer patients and cancer free individuals were screened for novel and previously 
identified loci by SNP array technology. The findings of susceptibility loci represent 
considerable progress toward blood sample mediated screening for CRC risk, although 
identification of additional risk loci are required for predictive purposes.   
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SCIENTIFIC AIMS 
 
The general aim of this thesis was to identify chromosomal DNA alterations and 
corresponding genetic transcriptional events associated to colorectal tumor progression and 
survival. 
 
The specific aims were to: 
   Define aberrant chromosomal DNA regions that discriminate between early and late 
colorectal tumors 
   Determine specific genetic events associated to aberrant DNA that potentially provide 
biomarkers for tumor progression and survival 
   Investigate the importance of p53 gene functionality in relation to colorectal tumor 
progression and survival 
   Identify structural variation in normal colon mucosa that may predispose for familial 
colorectal cancer 
 
 METHODOLOGICAL CONSIDERATIONS 
  21
METHODOLOGICAL CONSIDERATIONS 
Study Design and Setup 
Tumor, normal colon biopsies and blood samples were collected from all patients operated for 
CRC during specific time periods (Figure 3) and at two Swedish hospitals specified below.  
Figure 3. 167 patients diagnosed with primary colorectal carcinoma were analyzed for genetic alterations in 
relation to their disease, as described in the Paper I-IV. All patients were of Caucasian, Northern European origin 
and have had surgery as the only treatment. The patients were from 2 different cohorts, based on where and 
when they were operated. Group A was operated between 1988-1992 in Uppsala, Sweden and Group B was 
operated between 2001-2005 in Uddevalla, Sweden.  The participation of patients in one or several studies is 
viewed in the diagrams and described in more detail in respective paper included in this thesis. 
Paper I 
Seventy-two CRC patients operated at Uppsala Hospital (Patient group A, Figure 3), Sweden 
were included and DNA for downstream analyses was isolated from primary tumors and 
visibly normal colon mucosa. p53 specific mutation and LOH profile for each of the 72 
patients were analyzed in relation to survival and Dukes stage.  
Paper II 
A total number of 73 CRC patients were included in this study. 32 were operated at Uppsala 
Hospital, Sweden (Patient group A, Figure 3) and subgrouped according to survival, while 41 
were operated at Uddevalla Hospital, Sweden (Patient group B, Figure 3) and subgrouped 
according to Dukes system  for tumor classification. From each patient, DNA was isolated 
from tumor tissue and from patients grouped according to survival, also from visibly normal 
colon tissue. Patients were analyzed with genome-wide arrayCGH to identify stage or 
survival specific major chromosomal aberrations.  
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Nineteen patients with recurrence-free, long-term survival (> 10 years after primary surgery), 
13 patients with very short survival time (< 1 year after primary surgery) (referred to as 
“alive” and “dead” in Paper II) and 32 patients according to Dukes A-D stages (n=8) were 
sub-grouped prior to analysis. For each of the groups described above, DNA was pooled prior 
to analysis. All hybridizations were performed in competition to a commercially available 
reference DNA (Clontech, BD Biosciences, Palo Alto, CA, USA) with one exception, where 
tumor DNA from long and short-term survivors was hybridized together. In addition, RNA 
from tumor tissue was extracted from 9 patients and subsequently analyzed for global 
expression patterns.  
Paper III 
Twenty-four CRC patients who underwent primary surgery at Uddevalla Hospital, Sweden 
were included in this study (Patient group B, Figure 3). Each Dukes A-D stage was 
represented by 6 randomly selected patients. From each patient, genomic DNA and total RNA 
was extracted from the same piece of tumor and visibly normal colon tissue. Patients were 
analyzed with 3 types of microarrays to identify specific and combined alterations in DNA, 
RNA and microRNA expression. DNA or total RNA was subsequently pooled according to 
Dukes staging prior to microarray analyses. The comparison of matched tumor to normal 
DNA or RNA enabled tumor specific interpretations, since tumor DNA was hybridized in 
competition with normal colon DNA. 
 
Paper IV 
Sixty CRC patients operated at either Uppsala Hospital or Uddevalla County Hospital, 
Sweden (Patient group A and B, Figure 3) were included and subgrouped (n=15) according to 
Dukes A, B, C and D histopathological classification system. Patients in Dukes A and B 
groups had at least 5 years recurrence free survival after primary surgery and patients in 
Dukes C and D died from colorectal cancer within 38 months after primary surgery. Dukes A 
and B patients represented a good prognosis group and Dukes C and D patients represented a 
poor prognosis group.  Genomic DNA from visibly normal colon mucosa was isolated from 
each patient and in addition DNA was also isolated from blood derived from 5 of the Dukes A 
patients. These blood samples were collected at least 5 years after primary operation 
(December 2008).  
 
Genomic DNA was pooled in sets of 5 patients, 3 sets (n=5) per Dukes group. Genomic DNA 
from 5 blood samples was also pooled. Altogether, 12 groups of pooled DNA from normal 
colon mucosa and 1 group of pooled DNA from blood were analyzed. A standard reference 
sample, NA10851 (Coriell Cell Repositories, Camden, NJ, USA) was included in the study 
design to minimize false positive calls in array-based CGH analysis (Carter 2007; Scherer, 
Lee et al. 2007). Exclusion of reference specific CNVs were enabled by hybridization of the 
NA10851 reference DNA to another purchased reference sample, a pool of DNA from normal METHODOLOGICAL CONSIDERATIONS 
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colon mucosa derived from six human cancer free donors (Biochain Institute Inc, Hayward, 
CA, USA).  
 
Genetic Analysis 
LOH and MSI detection by Microsatellite Allelotyping  
Microsatellites constitute highly polymorphic DNA regions composed of tandem repeats and 
are widely used as molecular markers for genetic applications, such as forensics, population 
linkage and gene dosage studies (Weissenbach, Gyapay et al. 1992; Urquhart, Kimpton et al. 
1994; Goldstein, Ruiz Linares et al. 1995). In cancer research, microsatellites are used to 
determine Loss of Heterozygocity (LOH) or more correctly, Allelic Imbalance (AI) to 
evaluate deletion or amplification patterns in specified DNA regions. Moreover, the discovery 
of Microsatellite Instability (MSI) in CRC and its linkage to HNPCC in 1993 (Thibodeau, 
Bren et al. 1993) emphasized the clinical importance of microsatellites as biological markers.  
 
In allelotype analysis (i.e. identification of LOH) tumor specific allelic patterns are compared 
to the corresponding patterns in normal tissue DNA (Skotheim, Diep et al. 2001).   
Heterozygous alleles display repetitive microsatellite motifs of different lengths and this 
particular repeat variation is determined by PCR amplification of microsatellite containing 
regions and subsequent detection of these PCR fragments by capillary electrophoresis. If the 
relative amounts of tumor and normal alleles are skewed, the relationship is defined as allelic 
imbalance. Microsatellite Instability (MSI) is characterized by the appearance of novel 
microsatellite alleles in tumor DNA where the actual number of microsatellite repeats differs 
from that of the two alleles present in normal tissue DNA. Microsatellite markers 
simultaneously provide information about MSI as well as LOH. Our intention was to analyze 
the patients for LOH within the area surrounding p53. A number of tumors displayed DNA 
with novel alleles that appeared in at least one of the analyzed microsatellite loci. 
Subsequently, BAT26, a well defined marker for MSI detection (Thibodeau, Bren et al. 1993) 
(Zhou, Hoang et al. 1998) was added to verify the occurrence of MSI. See Paper I for 
experimental details (Lagerstedt, Kressner et al. 2005). 
 
Mutation Analysis by DGGE and sequencing  
p53 mutations were primarily identified by Denaturant Gradient Gel Electrophoresis (DGGE) 
(Fischer and Lerman 1983) screening and further characterized by genomic DNA sequencing 
followed by a second sequencing procedure performed on cDNA (Lagerkvist, Stewart et al. 
1994). The principle of DGGE is based on double stranded DNA fragment melting behavior.  
Mutated DNA fragments denature at different points on an acrylamide gel compared to 
normal DNA and hence, give rise to different banding patterns. Each mutated fragment was 
reamplified by PCR and forwarded to sequencing in both sense and antisense direction by 
capillary electrophoresis separation.  For each genomic DNA PCR fragment with verified p53 
mutation, the procedure was repeated by sequencing of the corresponding cDNA fragment. 
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Microarray Analysis 
Since the first expression microarray was described in 1995 (Schena, Shalon et al. 1995), 
DNA microarray technology has become a common and powerful tool for large scale and 
high resolution genetic analyses. Different applications of the microarray technology have 
been developed through the years to enable investigations within various research areas such 
as population genetics and characterization of complex genetic diseases such as cancer.   
Subsequently, different microarray platforms for different applications have raised and five 
types of microarrays to study genetic variation in DNA, RNA and microRNA were used in 
Papers II, III and IV, included in this thesis (described below). 
Principles of microarrays  
Technically, there are two major microarray categories, namely one-color (e.g. Affymetrix 
arrays) and two-color arrays (e.g. Agilent arrays). The difference essentially refers to 
hybridization performance and type of data generated from scanned images. One-color arrays 
are based on hybridization of one source of DNA or RNA while two-color arrays are based on 
hybridization of two sample sources and thereby generate a ratio derived from the two 
analyzed samples.  One–color performance involves fluorescent dye labeling (often Cy-3, Cy-
5 or biotin) of one sample which is then solely hybridized to the array (Paper III). In two-
color performance, two samples are labeled with two different dyes (typically Cy-3 and Cy-5) 
which are simultaneously hybridized to the array in a competitive manner (Paper II, III and 
IV). After hybridization one- and two-color arrays are treated similarly during scanning where 
the fluorescence of one or two fluorophores is visualized by laser beam excitation at defined 
wave lengths and subsequently detected as images of the array slide. Image analysis and 
quantification is described below. 
 
Array-based Comparative Genomic Hybridization  
Array-based Comparative Genomic Hybridization (arrayCGH) comprises high resolution 
techniques that enable genome-wide identification of genetic aberrations such as 
amplifications and deletions in genomic DNA samples. In this thesis arrayCGH constitutes 
the central analysis tool for the purpose of defining tumor progression on the basis of genetic 
DNA aberrations.  Originally, CGH was developed to evaluate DNA copy number changes 
across the genome by co-hybridization of differently labeled sample and reference DNAs to 
normal metaphase chromosomes (Kallioniemi, Kallioniemi et al. 1992). Today CGH is 
essentially improved and replaced by array-based CGH, which was introduced in the late 
1990s (Pinkel, Segraves et al. 1998; Pollack, Perou et al. 1999).  cDNA, tiling BAC and 
oligonucleotide arrayCGH platforms were used and details about performance and analysis 
are described in Paper II, III and IV.  
Gene and  microRNA expression microarrays  
Gene expression analysis in Paper II and III were performed on 44k whole genome 
oligonucleotide microarrays (Agilent Technologies) (Skotheim, Lind et al. 2005) and one-METHODOLOGICAL CONSIDERATIONS 
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color 15k human miRNA microarrays (Agilent Technologies) (Wang, Ach et al. 2007) were 
used for oligonucleotide-based microRNA expression analysis (Paper III). 
 
Preprocessing of Microarray Data 
Microarray preprocessing includes several steps where fluorescence intensities from each 
probe specific spot location on the array are converted into applicable data. Image analysis 
tools, such as Genepix (Axon Instruments Inc, Foster City, CA, USA) (Paper II) and Feature 
Extraction (Agilent Technologies) (Paper II, III and IV) were used to extract probe-specific 
values from the array images. Spotted arrays (BAC and cDNA arrays) require verification of 
probe location on the array, which is performed by alignment of a grid (a probe locus map) to 
the microarray image. This step is not necessary for in situ synthesized oligo arrays, since 
each probe position is defined by the array design. Next, signal and background intensities are 
calculated for each probe and imported into appropriate software for subsequent 
quantification, normalization and further data analysis. Preprocessing details for microarrays 
and analysis formats are summarized in Table 2.  
Statistical Analysis of Microarray Data 
The frequently discussed and well known complexity of microarray data is due to high 
dimensionality and high levels of noise - which in essence is a statistical problem 
(Kristiansson 2007).  To accomplish the aims of microarray studies it is therefore of great 
importance to establish clearly defined hypotheses and select appropriate statistical tools for 
data analysis. Analysis of arrayCGH data aims to determine DNA segment alterations in 
terms of gain and loss of subchromosomal regions of various sizes. Expression analyses 
measure genes or microRNA transcripts that are differentially expressed between samples or 
conditions. Different strategies for data analysis were used depending on the array format and 
are described in Table 3. 
 
Strategies to combine and correlate microarray data  
In Paper III, aberrant tumor specific DNA segments were combined with the corresponding 
differentially expressed genes and microRNAs. The aim was to sort out regions and genes 
that represent genetic events present in more than one genetic level (e.g. DNA and mRNA or 
microRNA). In addition, stage specific alterations were evaluated in order to determine 
genetic events that discriminate between early (Dukes A and B) and late (Dukes C and D) 
tumor progression. All combined analyses were based on DNA segments called as aberrant by 
the CBS DNA segmentation algorithm (Olshen, Venkatraman et al. 2004) and these segments 
were subsequently tested for overrepresentation of differentially expressed genes or 
microRNAs as follows.  
 
First, probes from the microarray were mapped to NCBI Entrez (build 18) genes or 
microRNAs within the region. The proportion of differentially expressed genes was compared 
to the entire genome and enrichment was then tested using Fisher’s exact test. The test of 
interaction was performed for significant alterations over the entire genome, each METHODOLOGICAL CONSIDERATIONS 
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Table 2. Methods and software for microarray preprocessing and data analysis presented for each of the 7 formats used in our studies. “BG Sub” is short for background 
subtraction and refers to correction for background signal intensities for each probe locus prior to analysis. Image analysis software converts probe specific signal intensities of 
each array into applicable data, summarized in a data result file that is imported and subsequently analyzed in another software or database. “Manufacturer” refers to where 
microarray slides are produced. 
          
     Preprocessing Software   
    
  Microarray Channel BG  Sub Normalisation Image  analysis  Statistical  Analysis Manufacturer
    
Paper II                                 
27k cDNA   arrayCGH  2-color    Yes  Lowess    GenePix Pro 4.0
1 BASE
3   Swegene
5 
32k tiling BAC  arrayCGH  2-color    Yes  Lowess    GenePix Pro 4.0
1 BASE
3   Swegene
5 
44k oligo  expression  2-color    Yes  Lowess    Feature Extraction 7.5
2 GeneSpring 7.2
2   Agilent 
                
Paper III                  
4x44k oligo  arrayCGH  2-color     No  Median    Feature Extraction 9.1
2 Bioconductor
4   Agilent 
4x44k oligo  expression  2-color     No  Lowess    Feature Extraction 9.1
2 Bioconductor
4   Agilent 
8x15k oligo  microRNA  1-color     No  Quantile-quantile    Feature Extraction 9.5
2 Bioconductor
4   Agilent 
     
Paper IV                         
105k oligo  arrayCGH  2-color     No  Lowess    Feature Extraction 9.5
2 CGH  Analytics  3.4
2   Agilent 
                
Normalisation methods: Lowess (Yang, Dudoit et al. 2002), Median (Smyth and Speed 2003) or quantile-quantile (Bolstad, Irizarry et al. 2003) 1 Axon Instruments Inc, 2 
Agilent Technologies 3 BioArray Software Enviroment, http://base.thep.lu.se/  (Saal, Troein et al. 2002), 4 statistical language R 2.7.2 (R Development Core Team 2009), 5 
Swegene Centre for Integrative Biology at Lund University (SCIBLU). 
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Table 3. Preprocessed microarray data analyses were performed by application of suitable strategies for specified datatypes. Further details are available in Paper II-IV. 
         
    Analysis Array  coverage
  Microarray Type  Tool  Ref Number of 
clones/probes 
Human 
genes/transcripts  
               
Paper II                
    
27k cDNA   arrayCGH  DNA 
aberration 
CGH Plotter  1    27k  10978   
               
32k tiling BAC  arrayCGH  DNA 
aberration 
CGH Plotter  1    32k  18900   
               
44k oligo  expression  mRNA 
expression 
No gene specific 
analysis applied 
   44k  33000   
              
Paper III    
               
4x44k oligo  arrayCGH  DNA 
aberration 
CBS 2    44k  19003   
               
4x44k oligo  expression  mRNA 
expression 
Moderated 
T-statistics, FDR 
4   44k  38896   
               
8x15k oligo  microRNA  microRNA 
expression 
Moderated 
T-statistics, FDR 
4   15k  509   
    
Paper IV                
               
2x105k oligo  arrayCGH  CNV 
 
ADM-2 3    105k  19003   
CNV, Copy Number Variation; FDR, False Discovery Rate; CBS, Circular Binary Segmentation; ADM, Aberration Detection Method 2; Ref, References: 1) (Autio, 
Hautaniemi et al. 2003) 2) (Olshen, Venkatraman et al. 2004) 3) (Lipson, Aumann et al. 2006) 4) (Benjamini and Hochberg 1995; Smyth 2004) METHODOLOGICAL CONSIDERATIONS 
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chromosome and each segment according to the CGH microarray. Gene expression patterns 
for genes within the candidate regions were also evaluated by linear regression (described 
above), followed by selection of the regulated genes with significant difference between 
Dukes A, B and C, D or A, B, C and D (Lagerstedt, Kristiansson et al. 2009). 
Ethical approval 
All analyses performed in Paper I-IV were approved by the Ethics Committee at the 
Sahlgrenska Academy, Sahlgrenska University Hospital, University of Gothenburg, Sweden. RESULTS 
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RESULTS 
Combined p53 mutation and LOH in relation to colorectal 
tumorigenesis and progression (Paper I) 
Among the 72 patients included in this study, Dukes stage was a predictor of disease specific 
mortality. Mutation analyses of all p53 exons revealed that 60% of the tumors contained 
mutation in at least one exon and several tumors had more than one mutation. p53 mutation 
did not predict survival. Four polymorphic markers, two within (I1p53 and Cd72), one 
upstream (D17S938) and one downstream (D17S720) of the p53 gene were analyzed for Loss 
of Heterozygocity (LOH).  59% of the analyzed tumors showed AI in one or more loci when 
all four markers were taken into account.  
 
Patients with LOH indicated by the D17S720 microsatellite marker, located downstream of 
the p53 gene had decreased survival compared to patients with retained heterozygocity at this 
locus (p<0.05). No differences detected by any other marker or combination of markers were 
related to survival.  34 % (24/71) of the tumors displayed combined p53 mutation and LOH, 
which was considered equal to ablated p53 function by loss of both alleles (non-functional 
p53
-/-).  The p53 gene was altered by mutation or LOH (functional, p53
+/-) or the combination 
of both in 76 % (54/71) of the analyzed tumors. Subsequently, 24 % of the tumors displayed 
two intact copies of the p53 gene (functional p53
+/+) as defined by our approach. Neither of 
the groups characterized by different p53 functional status, in terms of mutation and/or LOH, 
predicted survival in the current material.  
Recurrent DNA aberrations in relation to colorectal tumorigenesis 
and progression (Paper II and III) 
In this section, results from both papers are presented together. There are two notable 
differences between the studies, namely hybridization conditions and data analysis strategies, 
which are described in detail in the Methodological Considerations section. 
Summary of genome-wide DNA aberrations (Paper II and III) 
The proportion of aberrant DNA increased with tumor progression, defined as early (Dukes A 
and B) versus late stage tumors (Dukes C and D) (Figure 4d). Accordingly, the number of 
altered chromosomes also increased with tumor progression. Dukes C showed the highest 
figures considering the proportion of aberrant DNA as well as the number of altered 
chromosomes (Figure 4d). The most frequent aberrations identified in colorectal tumors and 
independent of tumor stage were gain on chromosomes 7, 13 and 20 and loss of 18, although 
quantitative DNA alterations were identified in each chromosome. Aberrations that appeared 
to discriminate between early and late colorectal tumors and thus recurrently and exclusively 
observed in Dukes C and/or Dukes D, were loss of 8p and gain of 7q, 8q and 13q. 
 RESULTS 
  30
mRNA genes
Genes with consistent direction
A
B
D C
0
50
100
150
200
250
A
B
C
D
0
500
1000
1500
2000
2500
3000
G
e
n
e
s
 
w
i
t
h
 
D
i
f
f
e
r
e
n
t
i
a
l
 
E
x
p
r
e
s
s
i
o
n
G
e
n
e
s
 
w
i
t
h
 
C
o
n
s
i
s
t
e
n
t
E
x
p
r
e
s
s
i
o
n
 
A
n
d
 
D
N
A
 
a
l
t
e
r
a
t
i
o
n
Groups Dukes A-D
B
C
D
A
0
20
40
60
80
100
120
140
AB
D C
0
2
4
6
8
10
12
14
16
18
m
i
c
r
o
R
N
A
s
w
i
t
h
 
D
i
f
f
e
r
e
n
t
i
a
l
 
E
x
p
r
e
s
s
i
o
n
m
i
c
r
o
R
N
A
s
w
i
t
h
 
C
o
n
s
i
s
t
e
n
t
E
x
p
r
e
s
s
i
o
n
 
A
n
d
 
D
N
A
 
a
l
t
e
r
a
t
i
o
n
microRNAs
microRNAs with consistent direction
Groups Dukes A-D
 
A
B
C
D
A B
C
D
B
A
D
C
0
100
200
300
400
500
600
700
S
r
t
u
c
t
u
r
a
l
l
y
A
b
e
r
r
a
n
t
 
D
N
A
 
(
M
b
a
s
e
s
)
Total DNA alterations
Gain Loss
Groups Dukes A-D
Number of Aberrant Chromosomes
Amount of Aberrant Genomic Content (%)
Paper II
Paper III
0
5
10
15
20
25
ABCD
0
5
10
15
20
25
N
u
m
b
e
r
o
f
 
A
b
e
r
r
a
n
t
 
C
h
r
o
m
o
s
o
m
e
s
P
r
o
p
o
r
t
i
o
n
 
o
f
 
A
b
e
r
r
a
n
t
 
G
e
n
o
m
i
c
C
o
n
t
e
n
t
(
%
)
Groups Dukes A-D
 
c) 
a)  b) 
Fig 4. Colorectal tumor progression visualized by individual or combinations of DNA aberrations and mRNA or microRNA expression. Figure a-d summarize Dukes A, B, C and D specific: a) 
mRNA gene distribution (red line) and genes with combined DNA and mRNA alterations (blue line), b) microRNA distribution (red line) and genes with combined DNA and microRNA 
alterations (blue line), c) DNA alteration in terms of total number of aberrant DNA sequences (blue line), lost sequences (dashed line) and gained sequences (semidashed line), d) genetic DNA 
aberrations presented as the proportion of aberrations per whole genome (line) and as the number of aberrant chromosomes (dashed line). Figures from Paper II and III are indicated by blue 
triangles and turqoise circles, respectively.  
d) 
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Genome-wide DNA aberrations (Paper II) 
DNA aberrations in Dukes A-D 
7 %, 4 %, 15 % and 12 % of BAC-clones representing autosomal chromosomes were altered 
in Dukes A, B, C and D tumors, respectively and the number of altered chromosomes was 12, 
14, 20 and 17. Equal amount of loss was observed in chromosome 18 in both Dukes A and B 
and C and D tumors, while tumor DNA from Dukes C and/or D displayed additional gains in 
chromosome 7, 8, 19 and 20 compared to Dukes A and B.  
 
DNA aberrations in late stage tumors (Dukes C and D) 
Major losses of the short chromosomal arm 8p and a region on 21q were observed in Dukes D 
but not in Dukes A, B or C. Gains specific for late stage tumors were parts of both 7p and 7q, 
the majority of chromosome 8q as well as parts of 19p and 20p (Table 4). 
 
DNA aberrations in tumors from long and short-term survivors 
Major alterations were found on chromosomes 8, 13, 18 and 20, but DNA from tumors 
derived from long-term (>10 years survival after CRC operation) patients only displayed 
large-scale aberrations on chromosomes 13 and 20 (Fig. 2 in Paper II). In tumor DNA from 
short-term survivors (< 1 year survival after CRC operation), chromosomes 8q and 13q 
showed major regions with gain, while losses were observed at chromosomes 8p, 18 and 21 
(Fig. 2 in Paper II) (data not shown). When tumor DNA from long- and short-term survivors 
were hybridized in competition to each other, three chromosomes displayed major DNA 
aberrations. Gained regions were observed on chromosome 8, 9, 13 and a major loss on 
chromosome 8 (Table 4). 
Genome-wide DNA aberrations (Paper III) 
Tumor specific DNA alterations increase with progression, defined as early (Dukes A and B) 
versus late tumors (Dukes C and D) (Figure 4c and Fig. 2 in Paper II). Dukes A, B C and D 
tumors displayed DNA alterations in 4, 4, 21 and 16 percent of the genome when compared to 
normal colon tissue (Table 2 in Paper III) where 4 chromosomes were altered in Dukes A, 6 
in Dukes B, 15 in Dukes C and 14 in Dukes D (Table 2 in Paper III). Distributions of genes 
that map to these regions are summarized in Figure 3. 
 
Minimal Common Regions (MCR) in Dukes A, B, C and D 
In Dukes A, B, C and D groups, chromosomes 1-11, 13-18 and 20-21 showed 102 Minimal 
Common Regions (MCRs); 78 % (80) were gained and 22% (22) were lost regions 
(Supplementary List 1). Overall, the aberrations correspond to 30 % of the genome (X and Y 
chromosomes excluded). 14 % of the aberrant DNA bases covered by MCR regions were 
altered in at least 3 out of 4 Dukes groups (ABCD, ABC, ACD or BCD) and located to 
chromosomes 7p, 13q, 18 and 20. Chromosomes 20 (41 Mb) and 13 (1 Mb) showed 
aberrations (gain) in all Dukes A, B, C and D stages. All combinations of MCRs that include 
either Dukes A, B or both, represented 55% of the MCRs (56) and were not considered 
relevant for tumor progression. RESULTS 
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Table 4. Chromosomal regions with DNA aberrations (> 2 Mb) in tumor DNA in relation to survival or tumor progression defined by Dukes staging of colorectal cancer. The 
indicated cytobands refer to aberration start points. Regions in bold are aberrant in late stage tumors. 
 
Hybridization 
Chromosome 
7  8 9  13 14  17  18  19 20 21 
                     
Paper II:  
Long vs Short 
Survival 
               
Gain  -  8p11.21 (6Mb) 
8q11.21 (16Mb) 
8q12.3 (18 Mb) 
8q21.3 (34 Mb) 
8q24.13 (22Mb) 
9q33.2 (17Mb)  13q12.2 (9Mb) 
 
- -  -  -  -  - 
Loss  -  8p21.3 (13 Mb)  -  -  -  -  - - - 
Paper II : 
Dukes A+B 
              
Gain  7q36.1 (11 Mb)  8p11.21 (6 Mb)   13q12.11  (33  Mb) 
13q21.33 (8 Mb) 
13q31.3 (22 Mb)
      19p13.3 (2 Mb)  20q11.1 (34 Mb)  - 
Loss  - -  - - -  -  18p11.32  (8  Mb) 
18q11.2 (21 Mb) 
18q21.2 (21 Mb) 
- - - 
Dukes C+D                
Gain  7p22.3 (5 Mb) 
7p15.3 (33 Mb) 
7q36.1 (11 Mb) 
8p11.21 (6 Mb)b 
8q22.1 (4 Mb) 
8q23.3 (28 Mb) 
- 13q12.11  (33  Mb) 
13q21.33 (8 Mb) 
13q31.3 (22Mb)
- -  -  19p13.3  (2  Mb) 
19p13.3 (17 Mb) 
20p13 (7 Mb) 
20p12.1 (7.4 Mb) 
20q11.1 (34 Mb)
- 
Loss  -  8p23.3 (36 Mb)a  - - -  -  18p11.32  (8  Mb) 
18q11.2 (21 Mb) 
18q21.2 (21 Mb) 
- -  21q21.1 (5 Mb)a 
Paper III:  
Dukes A+B 
              
Gain  - -  - 13q12.11  (4  Mb) 
13q12.13 (3 Mb) 
13q21.1 (2 Mb) 
- -  -  -  20p13  (62  Mb)  - 
Loss  - -  - - -  -  18q11.2  (54  Mb)  - - - 
Dukes C+D                
Gain  7p11.1(20Mb)a,b  8q11.1 (91 Mb)  9q34.3 (3 Mb)a  13q12.11 (4 Mb) 
13q12.12  (3 Mb) 
13q12.13 (3 Mb) 
13q12.3  (29 Mb)c 
13q21.1 (2 Mb) 
13q21.31 (11 Mb)c 
13q22.1 (40 Mb)c
- -  -  -  20p13  (62  Mb)  - 
Loss    8p23.2 (33 Mb)a  - -  14q12 (3 Mb)a  17p13.3 (22 Mb)a  18q11.2 (54 Mb) 
18p11.32 (17Mb)b,c 
- -  21q21.1 (14 Mb) 
21q11.22 (7 Mb)a 
a) The region was only indicated as aberrant in Dukes D, b) the aberration starts on the p-arm, spans over the centromere and covers parts of the q-arm. c) a part of the aberrant DNA region is 
only observed in late Duke stages.  RESULTS 
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Minimal Common Regions (MCRs) in late stage tumors (Dukes C and D) 
Overall, 75 % of the MCRs were found in Dukes C and/or D: 23 % of aberrant bases covered 
by MCR regions were only present in Dukes C and D, 39 % only in Dukes C and 13 % of the 
aberrant bases were only present in Dukes D. MCRs in Dukes C and D were located to 
chromosomes 8q, 13q, 18p and 21q and MCRs in Dukes D only included 1p, 7q, 8p, 9q, 11q, 
13q, 14q, 15q, 17p and 21q (Supplementary List 1) (Table 4). 
 
mRNA and microRNA expression in colorectal tumorigenesis and 
progression (Paper III) 
Summary of genome-wide mRNA changes between tumor and normal colon tissue 
There was no clear relation between the number of differentially expressed genes and tumor 
progression (Figure 4a) where 6, 8, 8 and 6 percent of the genes showed differential 
expression (FC>1, FDR<0.5) in tumor tissue compared to normal colon tissue in Dukes A, B, 
C and D. The gene distribution between Dukes groups is summarized in Figure 5 (details in 
Table 3 in Paper III). In all Dukes groups, the number of differentially expressed genes was 
consistent  between the different chromosomes, except for chromosome 13 where Dukes D 
showed more than twice as many up-regulated genes compared to Dukes A-C (p=10
-11, 
Fisher’s exact test) (Table 3 in Paper III). 
 
Summary of genome-wide microRNA changes between tumor and normal colon tissue 
There was no relation between tumor stage and the number of regulated microRNAs (Figure 
4b). Dukes A, B, C and D tumors showed 17, 21, 18 and 15 percent differential expression 
(FC>0.5, FDR<0.05) compared to normal colon tissue. Dukes B and C showed microRNAs 
with differential expression in all chromosomes. Dukes A showed no such expression in 
chromosome 10 and Dukes D lacked differentially expressed microRNAs in chromosomes 10 
and 12 (details in Table 4 in Paper III). 173 microRNAs showed differential expression in one 
or combinations of Dukes groups and 55 were regulated in all Dukes groups (Figure 5).   
 
microRNA expression in relation to late Dukes stages (C and D) 
Six microRNAs showed significant change in expression levels between Dukes A and B and 
Dukes C and D stages (Table 5 in Paper III). Two were altered in Dukes D only and 4 in 
Dukes A and B but not in C and D. 
Combination of DNA aberrations and mRNA/microRNA expression 
in relation to colorectal tumorigenesis and progression (Paper III) 
Genome-wide interaction of DNA alteration and mRNA expression 
Each Dukes group showed genome-wide correlation between genomic DNA aberrations and 
transcriptional differential expression (Supplementary List 2). 31% (6498/21261) of human 
genes were altered in any of Dukes A, B, C or D stages at either the DNA or RNA level (or 
both, Figure 5). 1231 of these genes (19 %, 1231/6498) were altered in all Dukes stages and RESULTS 
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Figure 5. Gene distribution in Dukes A, B, C and D groups in five subsets dependent of analysis; DNA (blue), mRNA (red), microRNA (green), combined DNA and mRNA with consistent 
direction (purple) and total number of combined DNA and mRNA genes (yellow). The number of genes or microRNAs that are common in Dukes A, B, C and D are presented in the light 
green circles ( ) at the base of each “Vennflower” and those that are common between A and B, B and C, C and D are displayed between overlaid petals. Observe that the values indicated by 
each individual leave refer to the total number of genes or microRNAs for that Dukes stage. RESULTS 
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406 genes (6 %, 406/6498) showed alterations with consistent direction, i.e. up-regulation in 
regions with gain or down-regulation in regions with loss (Figure 5). 
 
Chromosomal interactions of DNA alterations and mRNA expression 
Chromosomes 4, 8, 13 and 20 displayed interactions between DNA alterations and 
differentially expressed genes when whole chromosomes were tested separately 
(Supplementary List 2). The number of chromosomes with significant interaction increased 
with tumor progression according to Dukes staging system; Dukes A showed the least number 
of interactions (1) and Dukes D the most (4). Chromosome 20 displayed interactions in Dukes 
A, B and D (p<0.05, Fishers exact test) and a trend in Dukes C (p<0.1) while chromosome 8 
showed interactions in Dukes C and D (p<0.05, Fishers exact test) (Fig. 2 in Paper III). 
Chromosome 4 showed interactions in Dukes C and chromosome 13 in Dukes A and D 
(p<0.05) (Supplementary List 2).  
 
Segment interactions of DNA alterations and mRNA expression  
The number of DNA segments with significant interaction to mRNA differential expression 
increased with progression, according to the Dukes staging system (Figure 6). Dukes A 
comprised 3 segments (66 Mb), Dukes B 3 (23 Mb), Dukes C 5 (358 Mb) and Dukes D 7 
segments (244 Mb) with interaction. Eleven of the segments were present in at least two of 
the four Dukes groups. These segments were located to chromosomes 7, 8, 13, 18 and 20.  
 
Segment interactions of DNA alterations and mRNA expression in Dukes C and D or 
only Dukes D 
Three DNA segments with significant interaction to mRNA differential expression were 
identified only in Dukes C and D; gain of 8q22.1-22.3 (10 Mb), gain of 8q23.3-24.23 (25 Mb) 
and loss of 18q12.3-21.1 (5.4 Mb). Five regions were found only in Dukes D; gain of 7p11.1-
q21.11 (20 Mb), loss of 8p23.2-23.1 (3.5 Mb), loss of 8p21.2-12 (4 Mb), gain of 13q12.3-
q21.2 (29 Mb) and gain of 13q22.1-q34 (41 Mb) (Supplementary List 3).  
 
Genes of potential importance for carcinogenesis 
Sixteen up-regulated genes within segments with significant interaction were found in all 
Dukes groups and were all located to chromosome 20 (Supplementary List 4).  The segment 
covers 40 Mb on chromosome 20p11.21-20q13.33 (66% of the entire chromosome 20).  
 
Genes of potential importance for tumor progression 
The DNA segments with significant interaction to mRNA expression contained 41 genes that 
discriminated between early and late tumor stages such that they were differentially expressed 
in either Dukes A and B or Dukes C and D. Sixteen genes were regulated in only Dukes C 
and D, 21 genes in only Dukes D and 5 genes were regulated in Dukes AB or ABC but not in 
D. A full 90% (36) of these genes showed a consistent mRNA expression in relation to DNA 
alteration, i.e. up-regulation in regions with gain or down-regulation in regions with loss. Four 
of these genes were located to chromosome 7p (regulated in Dukes D), three at 7q (Dukes C  
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and D), five at 8p (Dukes D), six at 8q (Dukes C and D), 19 at 13q (14 Dukes C and D, 5 
Dukes D), and five at 18q (2 Dukes C and D, 3 Dukes D) (Table 5).  
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Figure 6. Genome-wide DNA aberrations in Dukes A, B, C and D. Thresholds for aberrant DNA segments with 
gain and loss are indicated by dashed lines and segments with significant interaction between DNA and 
differential expression are highlighted in red at the base of each plot.RESULTS 
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Interaction between DNA alternations and microRNA expression 
Twenty-three microRNAs were located to significantly altered DNA segments in Dukes A, B, 
C or D in chromosomes 1, 4, 7-9, 13, 17, 18 and 20.  Three, 3, 16 and 16 microRNAs were 
altered in Dukes A, B, C and D respectively. One microRNA (miR-663 at 20p11.1) was 
upregulated within a gained region in all Dukes stages. All microRNAs in segments with 
significant interaction in Dukes C and D showed differential expression in Dukes A and B, 
only that these microRNAs were located in regions without altered DNA segments in Dukes 
A and B. No regions with interaction between microRNAs and DNA alterations were found 
to discriminate between early and late Dukes tumor stages. 
 
Structural DNA variation in normal colon mucosa from colorectal 
cancer patients (Paper II and IV) 
In this section, results from Paper II and IV are presented together. There are two notable 
differences between the studies, namely experimental setup and data analysis strategies which 
are described in detail in the Methodological Considerations section. 
 
Structural variation in normal colon DNA, in summary (Paper II and IV) 
Nine verified CNV regions were common between the total amount of 205 (5 %) CNVs 
found by oligo microarrays (Paper IV) and 28 (36 %) CNVs observed by tiling BAC arrays 
(Paper II). All overlapping CNVs were verified CNV regions by comparison to the Database 
of Genomic Variants (DGV).   
 
Structural Variation in normal colon DNA from long and short-term survivors (Paper 
II) 
Twenty-eight verified and 2 novel CNV loci were identified in normal colon DNA from long 
and short-term survivors (Table 3 in Paper II). The 2 novel CNV loci identified at the time of 
analysis (2006) were, however, confirmed CNV loci according to the current database 
information (DGV updated March 11, 2009, Build 36 (Mar. 2006)).  
 
Structural Variation in normal colon DNA (Paper IV) 
Genome-wide analyses of DNA from 12 normal colon mucosa and one blood sample 
specimen from patients with colorectal tumors, revealed a total number of 774 potential CNV 
loci calls. 205 calls were identified in at least two specimens out of which 118 (57%) calls 
were verified CNVs, according to the Database of Genomic Variants (DGV) (Iafrate, Feuk et 
al. 2004; Zhang, Feuk et al. 2006) and 87 were novel at the time of analysis. Eight potential 
CNVs were found in more than 50% and 5 in more than 75% of the specimens (Table 1A  in 
Paper IV). 67% (58) of the CNVs covered regions that harbor at least one gene. Three novel 
variations, present in 3 out of 12 groups, potentially discriminate between early (Dukes A and 
B) and late (Dukes C and D) stage.  One CNV, identified at 10q21.1, was present in late  
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Table 5.  41 genes located within altered DNA segments in late CRC tumors (Dukes C and/or D). Genes showed 
differential expression in either Dukes A, A-C, Dukes C and D or only Dukes D. ”Alteration DNA/RNA” refers 
to alterations in late Dukes stages. 
Dukes A genes were significantly downregulated only in Dukes A and expression increases with increased 
Dukes stage. Dukes A-C genes were significantly upregulated only in Dukes A-C, but not in Dukes D. 
a Genes 
are located to significantly abberant segments without significant segment interaction between DNA and RNA. 
b 
Genes that are target for microRNAs identified in Paper II, Table 5. 
 
stages (2 Dukes C and 1 Dukes D) and two variations, at 15q21.3 (2 Dukes A and 1 Dukes B) 
and 2p15 (2 Dukes A and 1 Dukes B) was present in early stages, (Table 1B in Paper IV).
   
Genes Location 
Alteration 
DNA/RNA Protein  Function 
Dukes A         
  ITM2B  13q14.2 ↑ - Membrane
  A_32_P80587  13q13.1  ↑ -  Unknown Function 
Dukes A - C        
GTF2E2  8p12  ↓ -  Transcription Factor -Initiation 
  ESCO2  8p21.1  ↓ -  Acetyltransferase 
  PBK  8p21.1  ↓ -  Phosphorylation 
Dukes C & D       
  STX1A
b  7q11.23  ↑ ↑ Transport 
  CLDN4  7q11.23  ↑ ↓ Membrane-Development 
  CLDN3  7q11.23  ↑ ↓ Membrane-Development 
  NAT2 
 a  8p22  ↓ ↓  Associated to Cancer and Drug Toxicity 
  BLK 
 a  8p23.1  ↓ ↓  Signal transduction in B-lymphoid Cells 
  RPL7 
 a  8q21.11  ↑ ↑ Ribosome 
  RPL30  8q22.2  ↑ ↑ Ribosome 
  PABPC1  8q22.3 ↑ ↑ Translation Initiation 
  TATDN1  8q24.13  ↑ ↑ Hepatocarcinoma 
  FBXO32
b  8q24.13  ↑ ↓  Phosphorylation  Dependent  Ubiquitination 
  EXOSC8  13q13.3  ↑ ↑ RNA  processing 
  C13orf7  13q31.1  ↑ ↑ Unknown  Function 
  RANBP5  13q32.2  ↑ ↑ Transport 
  TPP2  13q33.1  ↑ ↑ Proteolys 
  SLC14A1-002  18q12.3  ↑ ↑ Transport 
Dukes D       
  IGFBP3 
a  7p13  ↑ ↑ Growth-IGF 
  URG4
  a  7p13 ↑ ↓ Hepatocarcinoma
  Hs648110 
 a  7p15.2  ↑ ↑  Unknown Function  (Ribosome) 
  C7orf46 
 a  7p15.3  ↑ ↑ Unknown  Function 
  WDR67  8q24.13  ↑ ↑ Unknown  Function 
  RFXAP  13q13.3  ↑ ↑  Transcription Factor -Development 
  ALG5  13q13.3  ↑ ↑ Glycosylation 
  NHLRC3  13q13.3  ↑ ↑ Unknown  Function 
  KIAA1704  13q14.12  ↑ ↑ Unknown  Function 
  CAB39L  13q14.2  ↑ ↑ Unknown  Function 
  THSD1  13q14.3  ↑ ↑ Extracellular  Matrix 
  AL831999  13q14.3  ↑ ↑ Unknown  Function 
  SPRY2  13q31.1  ↑ ↑ Signalling 
  TGDS  13q32.1  ↑ ↑ Unknown  Function 
  CLDN10  13q32.1  ↑ ↑ Membrane-Tight  Junction 
  SLC10A2  13q33.1  ↑ ↓  Transport -sodium/bile acid   
  ANKRD10  13q34 ↑ ↑ Unknown Function
  PCID2  13q34  ↑ ↑ Unknown  Function 
  AF263545  18q12.3  ↑ ↑ Unknown  Function 
  CD33L3  18q12.3  ↑ ↑ Membrane 
  ATP5A1  18q21.1  ↓ ↓ Transport 
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DISCUSSION 
General Summary 
In the current thesis, colorectal tumors and normal colon tissue were used as models to 
investigate the role and order of genetic events in relation to transformation from early to late 
tumor stage. Initially, we focused on a single gene; p53- by no doubt implicated in neoplastic 
development, to relate its genetic defects to progression and survival in colorectal cancer 
(CRC) patients. The results confirmed the importance of p53 in tumorigenesis, but did not 
generate any clear evidence concerning progression or survival. Next, we broadened our 
spectra by applying genome-wide array-based CGH analysis to a number of colorectal tumors 
subdivided according to Dukes stage or long or short-term survival. We observed a large 
number of DNA aberrations related to carcinogenesis and progression that were in agreement 
with previous and simultaneous reports. However, due to the complexity of the identified 
aberrations, it was difficult to distinguish primary from secondary events in relation to 
colorectal tumorigenesis. The general DNA aberration patterns were therefore confirmed by a 
second genome-wide arrayCGH study and further combined with matching mRNA and 
microRNA profiles. Thereby, DNA aberrations without any correlated alterations in mRNA 
and microRNA were excluded. The combined aberration patterns generated 41 genes and 6 
microRNAs with potential importance for colorectal progression. Finally, we investigated the 
occurrence of known and novel structural variations, CNVs, in DNA from normal colon 
mucosa from a cohort of CRC patients. Several known and novel CNVs appeared frequently 
in CRC patients but not in controls and were thus potentially associated to colorectal 
tumorigenesis. 
 
Large-scale techniques such as arrayCGH enable simultaneous identification and analysis of 
unbalanced structural DNA aberrations although breakpoints, translocations and inversions 
are difficult to determine due to lack of resolution. Nevertheless, the development of 
microarray-based techniques has enhanced the collection of genetic data in the search for 
diagnostic and predictive markers associated to cancer. During the first years following 
commercialization of expression arrays in the beginning of this century, huge amounts of 
microarray based studies were published in the field of cancer. However, due to various ways 
to collect tissue biopsies, different RNA extraction protocols and diverse approaches for 
analysis of already complex specimens, interpretation and in particular comparisons between 
studies were initially close to impossible. Subsequently, rules for “Minimal Information 
About a Microarray Experiment” (MIAME) was released (Brazma, Hingamp et al. 2001) and 
in addition, implementation of standards for microarray handling and analysis convey a more 
solid and convenient technique. Although improvements have increased the ability to generate 
trustworthy data, consensus genes with differential expression in colorectal cancer are low. 
Many different genes and panels of genes have been presented as of potential importance for 
colorectal carcinogenesis or progression (Cardoso, Boer et al. 2007; Nannini, Pantaleo et al. 
2009), but few if any have been proved reproducible enough for clinical applications.  
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One way to circumvent this problem was to evaluate expression data in relation to 
coordinated aberrations in DNA content and exclude differential expression without such 
correlations. However, combined analyses of this kind must be interpreted with caution, since 
functional consequences of DNA alterations are not always apparent.  DNA alterations do not 
necessarily induce subsequent and intuitively expected changes in expression, as reported by 
others (Platzer, Upender et al. 2002; Tsafrir, Bacolod et al. 2006).  
 
Which chromosomal aberrations distinguish early from late colorectal 
tumors? 
Genomic instability reflects the accumulation of genetic alterations that are frequently 
identified in colorectal tumors and provides growth advantages leading to clonal expansion. 
There is a wide agreement that recurrent genetic events most likely encompass genes of 
importance that may also drive the neoplastic transformation from normal epithelial cells to 
malignant tumors (Vogelstein and Kinzler 2004; Tsafrir, Bacolod et al. 2006). In contrary, 
others claim that genomic instability rather is a bystander effect that progress along with 
tumorigenesis as a result of malfunctional cell cycle activities (Grady 2004; Tsafrir, Bacolod 
et al. 2006).  Still, the origins of chromosomal abnormalities are elusive and a matter of 
debate.  
 
However, tumors with chromosomal instability (CIN) encompass diverse genetic changes and 
show substantial intratumor variability considering the patterns of genetic rearrangement. 
Since a subset of these changes is most often shared by all neoplastic cells within a tumor, a 
step-wise accumulation of genetic abnormalities is likely to appear during tumor growth 
(Heim, Mandahl et al. 1988).  This is evident, since the amount of genetic alterations in terms 
of entire chromosomes as well as subchromosomal aberrant lesions is recurrent and 
apparently increases with tumor progression (Ried, Heselmeyer-Haddad et al. 1999; Hermsen, 
Postma et al. 2002).  
 
In Paper II and III, genome-wide DNA alterations were characterized and correlated to 
colorectal tumor progression defined by Dukes A-D staging system (Lagerstedt, Staaf et al. 
2007; Lagerstedt, Kristiansson et al. 2009). The DNA patterns in general, as well as in both 
early and late tumor stages (defined as Dukes A and B versus Dukes C and D) were in 
agreement with previously published data (Ried, Heselmeyer-Haddad et al. 1999; Hermsen, 
Postma et al. 2002; Douglas, Fiegler et al. 2004; Nakao, Mehta et al. 2004; Jones, Douglas et 
al. 2005; Mehta, Nakao et al. 2005). Frequent early stage DNA changes include gain in parts 
of chromosomes 7p and 13q and whole chromosome 20 and loss in parts of chromosome 18q, 
Late stage alterations include gain of 7p, 7q, 8q, 13q and loss of 8p, 18p and 21q. 
Furthermore, our observations also indicate a to our knowledge novel association between 
late stage and poor prognosis tumors and loss of a 5Mb DNA segment on 21q21.1-2. Further, 
we have also found that the loss of 8p clearly and exclusively appear in Dukes D tumors as 
well as in tumors from patients with short-term survival.  
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In relation to Dukes A, B and D, Dukes C tumors display higher proportions of aberrant DNA 
distributed in an increased number of chromosomes (Figure 4d). We identified this particular 
pattern in two independent cohorts of patients by arrayCGH analyses on two different 
platforms (BAC and oligonucleotide) based on diverse principles. Dukes D tumors involved 
less aberrant DNA than Dukes C, which may indicate that Dukes D tumor clones contain “just 
right” genetic defects (Fodde, Smits et al. 2001) that convey the ability to give rise to distant 
metastases. Hence, the rate of aberrant genetic events should be high enough to hit necessary 
target genes, but still moderate enough to avoid cell death caused by excess genomic 
instability (Cahill, Kinzler et al. 1999). The exclusive properties of Dukes D clones, bearing 
obtained advantageous abilities, may surpass less adapted clones and thereby creating a more 
homogenous genetic composition within the tumor.  
 
Dukes D patients are diagnosed at an earlier age than the other patients in the present cohort 
(10 years earlier) which may be explained by two separate scenarios. Either a number of 
Dukes D tumors results from an earlier onset or alternatively, an increased development rate 
that does not follow the proposed stepwise progression model (Fearon and Vogelstein 1990). 
The latter scenario has actually been proposed by others although not specified as a 
phenomenon typical for Dukes D tumors (Weinberg 2007). The earlier onset may involve 
familial genetic events and consequently predispose for malignant disease by specific 
mutations or structural variation present in each and every cell. There are similarities to FAP 
and HNPCC hereditary variants, since these patients are diagnosed 10 or 20 years earlier than 
patients with sporadic disease. In case of the inherited or familiar scenario, the Dukes D 
genotype would thus contain genetic events predisposing for CRC and just await the right 
external tumor-favoring stimuli to trigger progression into malignant transformation.  
 
A central and apparent observation in analyses based on genomic DNA alterations is the 
increased properties of aberrant DNA in relation to early to late tumor progression (Ried, 
Heselmeyer-Haddad et al. 1999). Interestingly, this particular trend was also illustrated by 
combination of aberrant genetic events (Figure 4a-c). In Paper III, data from CGH 
microarrays were combined with data from mRNA and microRNA expression microarrays to 
identify tumor specific genetic differences in relation to colorectal tumor progression. DNA 
and RNA interactions significantly increased from early to late Dukes stages at the 
chromosomal, subchromosomal and gene level (Figure 4a and Supplementary List  2 and 3) 
and the interaction between DNA and microRNA significantly increased at the gene level 
(Figure 4b). Dukes C and D together showed an increased number of aberrant DNA segments 
compared to Dukes A and B. Interestingly the mRNA and microRNA expression patterns 
were not concordant with the genomic DNA alterations since the number of differentially 
expressed mRNA and microRNA transcripts decreased. This trend was negative in relation to 
tumor progression (illustrated in Figure 4a-b) which was in contrast to the positive trend 
generated from interaction of DNA segments and mRNA/microRNA expression. Dukes D 
showed the least number of regulated genes compared to all the other Dukes stages, including 
Dukes A. Thus, the total number of chromosomal gains represents the only variable that alone 
constitutes a genome-wide predictor of progression (Figure 4c).  Nevertheless, the number of DISCUSSION 
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combined Dukes D DNA and RNA/microRNA genes represents a higher or equal amount to 
that of Dukes C (Figure 4a-c). This suggests that despite lower amounts of possible RNAs or 
microRNAs, their combined effect illustrates a tumor with highly successful and devastating 
properties. This is in line with the hypothesis that some tumors acquire highly favorable 
changes and hence the capacity to metastasize to distantly located organs as discussed 
previously.  
 
Interactions in all Dukes A-D stages were only found in chromosome 20, which makes this 
region as a whole most likely related to colorectal carcinogenesis (Habermann, Paulsen et al. 
2007), Alterations in chromosome 20 have previously been studied thoroughly by others and 
correlation between gains and up-regulation has been observed (Carvalho, Postma et al. 
2009). Moreover, gains of large parts of chromosome 20 are present already in adenomas 
(Hermsen, Postma et al. 2002). In conclusion, the amount of aberrant DNA content as well as 
the number of correlated alterations in DNA and mRNA/microRNA, increases with 
progression from early to late tumor stage according to Dukes classification.  Further, our 
results suggest that Dukes D comprise tumors with a high degree of aberrant DNA that to 
some extent affect expression. Dukes D tumors display lower amounts of regulated mRNAs 
and microRNAs, which may reflect that only selective, highly essential pathways are 
activated.  
 
Does combined p53 mutation and loss of heterozygocity influence 
colorectal progression and survival? 
In Paper I, combined allelic loss and p53 mutation were considered equal to functional 
inactivation of the protein according to the “two hit-hypothesis” and as previously suggested 
considering p53 inactivation in CRC (Baker, Fearon et al. 1989; Forslund, Lonnroth et al. 
2001).   
 
Since patients with LOH downstream of the p53 gene showed decreased survival compared to 
patients with retained heterozygocity at this locus (p<0.05, log-rank test) this marker 
(D17S720) was the only variable that displayed difference predictive of outcome. Hence, 
ablated p53 function, according to our definition, was not associated to survival or any 
particular stage during the progression from early to late colorectal cancer.  
 
Nevertheless, 76 % of the analyzed tumors showed LOH or mutation in one or both alleles 
which confirms that p53 gene alterations are common events in colorectal tumors. 
Accordingly, structural p53 alterations probably occur at an early stage during neoplastic cell 
transformation from late adenoma to early carcinoma, as suggested in the Vogelstein model 
(Fearon and Vogelstein 1990). However, at the time of analysis, it was only recently reported 
that MDM2 was the main regulator of p53 activity and that some tumor suppressor genes, 
evidently even p53, were discovered to obtain haploinsufficient properties. Today, these 
genetic events are defined and characterized to a much greater extent. First, overexpression of 
MDM2 due to gene amplification has been identified in almost 10% of CRCs (Momand, Jung DISCUSSION 
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et al. 1998; Forslund, Zeng et al. 2008) though there is evidence that MDM2 overexpression 
does not always correlate to amplification (Forslund, Zeng et al. 2008). Abnormal activation 
of MDM2 can arise due to a polymorphism located in its promoter (Bond, Hu et al. 2004), 
which thereby attenuate p53 activity.  Second, a single mutant p53 protein has the ability to 
disable the tetrameric structure that otherwise constitutes the functional p53 oligomer, which 
was proposed as a possible explanation for haploinsufficiency (Santarosa and Ashworth 
2004). In conclusion, we found no association between tumor progression and functional p53 
inactivation, although p53 alterations were frequently observed in CRC tumors. However, 
deletions that occur downstream of the p53 gene may be indicative for increased disease 
specific mortality. 
Which genetic events are of importance for colorectal tumor 
progression? 
In Paper III, candidate regions from interaction analyses were identified at chromosomal arms 
7p (Dukes D), 8p (Dukes D), 8q (Dukes C and D), 13q (Dukes D) and 18q (Dukes C and D) 
that may encompass genetic events with impact on tumor progression. Gene expression 
patterns for genes within the candidate regions were evaluated followed by selection of 
regulated genes with significant difference between Dukes A, B and C, D or A, B, C and D. 
Fourty-one genes were located in these regions that were regulated in a way that discriminate 
early from late or metastatic tumor stage (Table 5). We identified two kind of candidate 
genes; 36 genes that only were significantly regulated in late stages of the disease and thus 
potential biomarkers and five genes that were regulated in Dukes A and B (or A, B and C) but 
not in C and D. The latter may be important for biological reasons, but are not interesting for 
predictive purposes (as biomarkers), since they are not measurable in Dukes C or D. 
Moreover, five of the potential biomarker genes have a reversed relationship between DNA 
alteration and the corresponding regulation (i.e. gain and down-regulation or loss and up-
regulation) which makes them less valid since they lack the structurally aberrant DNA basis. 
As described above, we found that differential gene expression present in early stage tumors 
sometimes vanish in the later stage probably as a consequence of the corresponding gain or 
loss that appear in these tumors. In regions with interaction between aberrant DNA segments 
and mRNA differential expression in late Dukes stage tumors (Dukes D), this situation 
occurred for five genes on chromosome 8p and 13q (Table 3). ESCO2, GTF2E2 and PBK are 
located to chromosome 8p and even though they have not previously been related to CRC, 
they are all implicated in processes in close relation to cancer events such as sister chromatid 
cohesion (ESCO2), transcription (GTF2E2) and p53 destabilization (PBK). Two genes on 
chromosome 13q were significantly down-regulated in Dukes A and expression gradually 
increases with increased tumor stage. Only one of the two genes at 13q (ITM2B) is known to 
encode a protein which is an integral membrane protein that may modulate cell survival (Lee, 
Jeong et al. 2007) (Table 3). 
 
Almost half of the candidate genes identified in Paper III (19/41) were located at chromosome 
13, which implies that regions with DNA and RNA interaction on chromosome 13 may be 
important for colorectal tumor progression. The composition of structural chromosome 13 DISCUSSION 
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alterations is complex and varies within different Dukes stages (Figure 6) (Gisselsson, Jonson 
et al. 2001). Furthermore, we found that Dukes D tumors showed significantly more regulated 
genes in chromosome 13 compared to the other Dukes stages, which represents a unique 
pattern in this data set since no other chromosome showed such differences in any group.  In 
contrast, recurrent gain as well as interaction of DNA segments and mRNA differential 
expression in chromosome 20 was observed in all Dukes stages.  Actually, sixteen genes 
located on chromosome 20 showed combined gain and upregulation in all Dukes A-D stages 
and no such combined events were found elsewhere in the genome. Among these genes were 
AURKA (Figure 7) and CSE1L, which were recently related to colorectal cancer (Bertucci, 
Salas et al. 2004; Camps, Grade et al. 2008). Loss of 18q is a frequent genetic event that is 
proposed to occur during progression from intermediate to late adenoma in the CRC 
progression model (Fearon and Vogelstein 1990). SMAD7 (Figure 7), have been presented as 
a key target gene, since it maps to a CRC susceptibility locus at 18q21 (Broderick, Carvajal-
Carmona et al. 2007; Pittman, Naranjo et al. 2009). In accordance, the expression patterns in 
Dukes A-D show a downregulation trend in the Paper III data set. Moreover, PTP4A3 (Figure 
7), also referred to as PRL-3, have been associated to metastatic CRC tumors and is located to 
a recurrently amplified region on 8q24 (Saha, Bardelli et al. 2001). In Paper II and III, this 
amplified region was observed in short-term survivors as well as late stage tumors and 
correspondingly, PTP4A3 showed a trend versus increased expression although below the 
cutoff for significantly altered expression (data not shown). 
 
 
The majority of the 36 candidate genes with alterations in Dukes C and D (Paper III) code for 
proteins implicated in transcriptional/translational processes, transport, membrane proteins 
and post-translational modification. Differential expression of TATDN1 and URG4 genes are 
related to hepatocellular carcinoma, which makes them interesting as the liver is the most 
common primary location for distant metastasis in CRC. NAT2 is involved in the metabolism 
of carcinogens and may affect risk of colorectal cancer (Bell, Stephens et al. 1995; Hein 2002) 
(1995). Finally, STX1A (7q11.23) and FBXO32 (8q24.13) were target genes for suggested 
candidate microRNAs miR-602 and miR-144 (miRBase Target Database, Wellcome Trust 
Sanger Institute; http://microrna.sanger.ac.uk/targets/v5/ ) (Griffiths-Jones, Saini et al. 2008).  
 
Surprisingly, as few as 6 microRNAs (including miR-602) was altered in a way that 
discriminate between Dukes A and B and Dukes C and D. In fact, 95 % of the microRNAs 
with interaction in C and D were also regulated in Dukes A and B, compared to 75 % in 
mRNA. Hence, there are few differences in microRNA regulation between early and late 
Dukes stages in CRC tumors, which suggest that microRNA may constitute regulators whose 
absence rather than presence promote malignancy in colorectal tumors. Accordingly, 
colorectal as well as other tumors recurrently display down regulation of microRNA in 
relation to normal cells (Blenkiron and Miska 2007). Nevertheless, we identified two 
microRNAs, miR-602 and miR-373 (Figure 7), which possibly impacts distantly metastatic 
tumors and four microRNAs of potential biological importance (Table 5 in Paper III). MiR-
373 was recently suggested as a promoter of metastasis in breast cancer cells (Huang, DISCUSSION 
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Gumireddy et al. 2008; Negrini and Calin 2008) but not previously related to metastasis in 
colorectal tumors. Up-regulation of miR-21 has been correlated to poor outcome in colorectal 
cancer patients (Schetter, Leung et al. 2008), but we did not find any clear evidence for that in 
the present data set. However, novel microRNAs are still rapidly arising and the number of 
microRNAs have almost doubled compared to those included in our analyses (718 today 
compared to 474 in 2007), implying that data should be interpreted with caution. 
 
In conclusion, 41 candidate genes and 6 microRNAs may be involved in the progression from 
early to late colorectal tumor stage and among these genes 36 represent candidate biomarkers. 
Moreover, SMAD7 and AURKA may represent genes that are of importance for colorectal 
tumorigenesis. Taken together, changes at the structural DNA level as basis for selection of 
biomarkers represent a robust rationale for characterization of tumor progression since the 
expected change in regulation has a stable intercourse with the clinical process. 
 
Can nonpolymorphic structural variation contribute to detection of 
familial colorectal cancer (Paper II and IV)? 
In recent years it has become evident that the human genome is more complex than 
previously appreciated, due to the presence of genetic variation between humans in terms of 
polymorphisms and structural variation (Iafrate, Feuk et al. 2004). These differences convey 
the possibility to identify specific variation associated to disease and subsequently provide 
diagnostic markers. In colorectal tumors, more than ten susceptibility loci (described in the 
introduction part) have already been discovered by SNP-based array technology. However, 
the power of these analyses has been questioned, since the odds ratios obtained within these 
studies are low (ranging from 1.1-1.5) (Easton and Eeles 2008; Houlston, Webb et al. 2008; 
Cheah 2009). Hence, identification of additional risk loci is required for predictive purposes 
next to colonoscopic examination and available markers for hereditary CRC.  
 
Since structural variation range from single nucleotides to several megabases and involves 
variable conformations/arrangements, it is essential to cross-examine both SNPs and all types 
of CNVs for exploration of phenotypic variation within tumors (Stranger, Forrest et al. 2007). 
In relation to SNPs, structural variation is likely to have even more impact on phenotypic 
variation and may thus serve to add further risk sites (Iafrate, Feuk et al. 2004; Redon, 
Ishikawa et al. 2006; Korbel, Urban et al. 2007; Stranger, Forrest et al. 2007). It is therefore 
desirable, not only to determine novel predictory biomarkers, but also nonpolymorphic, 
structurally variant markers aside from the existing SNP markers uncovered so far. Hence, 
sufficient numbers of diagnostic markers based on structural genetic aberrations and 
polymorphic sites would considerably benefit CRC patients in terms of early diagnosis and 
thereby improved survival.  
 
  In situ synthesised oligonucleotide microarray technology is an efficient tool for CNV 
detection (de Smith, Tsalenko et al. 2007). Moreover, oligonucleotide arrays provide genome-
wide sequence coverage which can not be ministered by SNP-arrays, since SNPs are not DISCUSSION 
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evenly distributed throughout the genome (Carter 2007).   Accordingly, high resolution 
oligonucleotide microarrays were used in Paper IV, to perform genome-wide scans for 
common DNA aberrations in visibly normal colon mucosa from colorectal cancer (CRC) 
patients.  118 known and 87 novel potential copy number variations (CNV) were observed in 
DNA pools grouped according to Dukes A-D system. The relation between identified known 
and novel CNVs are in agreement with other oligobased microarray studies (de Smith, 
Tsalenko et al. 2007; Camps, Grade et al. 2008).   Among these, 29 known and 8 novel CNVs 
were found in more than 50 % and 8 known and 5 novel CNVs were found in more than 75 % 
of the DNA pools, indicating that these potential CNVs are either frequent loci in Northern 
Europeans or CRC specific structural variants.   
 
The novel CNVs included three novel potential CNV regions that may discriminate early 
(Dukes A and B) from late (Dukes C and D) tumor stage, albeit present in as few as 25-30% 
of the analyzed samples. 58 out of the 87 novel CNVs, contained at least one gene. With few 
exceptions, genes within regions of structural variation do not contain known tumor genes, 
according to the majority of the GWAS performed to date (Easton 08). However, SMAD7, 
involved in TGFβ mediated activities (Boulay, Mild et al. 2003; Broderick, Carvajal-Carmona 
et al. 2007) (18q21.1), constitute an exception. In our data CHRNB4 (15q25.1) encodes a 
cholinergic receptor located within a region recently associated to lung cancer (Amos, Wu et 
al. 2008; Liu, Vikis et al. 2008) and represent the only tumor related gene present in CNVs in 
more than 50% of analyzed specimens. No genes were found in the regions of potentially 
novel CNVs that discriminate early from late tumor stage. 
 
Nine verified CNV regions were common between the total amount of 205 (5 %) CNVs 
found by oligo microarrays and 28 (36 %) tiling BAC arrays, used in Paper II. The overlap is 
satisfying, considering the notable differences between analysis platforms and strategies. 
Interestingly, one verified 1.5 Mb locus at 5q13.2 was identified in 12 out of 13 analyzed 
specimens including Paper II and IV samples as well as in DNA from blood and thereby 
indicate association to colorectal tumors. In conclusion, several known and novel 
nonpolymorphic structural variants were identified in normal DNA from CRC patients and 
may be predictive of familial colorectal cancer incidence. Clearly, however, these findings 
need further validation.  
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CONCLUSIONS 
Taken together, the results in terms of the genetic events presented within this thesis is 
summarized by their potential relevance within the different stages that defines the stepwise 
progression proposed to transform normal cells into malignant colorectal tumors (Figure 7). 
First, gain in parts of chromosome 20, encompassing cell-cycle regulating kinase AURKA, as 
well as p53 alterations and differential expression of microRNAs, may be involved in the 
development from adenoma to carcinoma. Second, several genomic DNA alterations appear 
to rise during progression defined as early (Dukes A and B) to late (Dukes C and D), namely 
loss of 18q and gain of 8q that harbor SMAD7 and PTP4A3, respectively. Third, distant 
metastatic potential may be associated to loss of 8p and increased expression of miR-373. 
Fourth, putative structural variants observed in normal colon mucosa may predispose for the 
onset of malignant transformation in familial sporadic CRC. Finally, there is a clear 
relationship between the increased properties of aberrant DNA content as well as the number 
of combined genetic events and tumor progression. Nevertheless, Dukes D tumors possibly 
develop in a way that does not fit into the stepwise progression model, as illustrated by earlier 
onset and less genetic aberrations.   
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Figure 7. This modified “Vogelgram” is supplied with additional genetic events of putative importance for
carcinogenesis or tumor progression, compared to the original model. Each event was observed in Paper I-IV
and has also been presented by others, as described in the discussion part. Blue indicates genomic DNA
aberrations, red refer to altered genes, either at the DNA, expression or both levels and green refer to microRNA
transcripts with differential expression. Each added genetic event is also indicated by a dashed arrow. 
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